



EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
03.10.2018 Bulletin 2018/40

(51) Int Cl.:
C07K 14/79 *(2006.01)* **C07K 16/18** *(2006.01)*
G01N 33/53 *(2006.01)* **G01N 33/48** *(2006.01)*

(21) Application number: **12818296.1**

(86) International application number:
PCT/IL2012/050269

(22) Date of filing: **24.07.2012**

(87) International publication number:
WO 2013/014669 (31.01.2013 Gazette 2013/05)

(54) **LACTOFERRIN FRAGMENTS AND USE THEREOF**

LACTOFERRINFRAGMENTE UND VERWENDUNG DAVON

FRAGMENTS DE LACTOFERRINE ET LEUR UTILISATION

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **24.07.2011 US 201161511056 P**

(43) Date of publication of application:
28.05.2014 Bulletin 2014/22

(73) Proprietor: **Carmel-Haifa University Economic
Corp.**
31905 Haifa (IL)

(72) Inventors:
• **ARIEL, Amiram**
26424 Kiryat Motzkin (IL)
• **LUTATY, Aviv**
2807256 Kiryat Ata (IL)

(74) Representative: **Becker Kurig Straus**
Patentanwälte
Bavariastrasse 7
80336 München (DE)

(56) References cited:
WO-A2-02/39883 US-A1- 2007 197 426

• **"Datasheet Lactoferrin (H-65): sc-25622", , 18
March 2012 (2012-03-18), page 1, XP055159360,
Retrieved from the Internet:
URL: [https://web.archive.org/web/20120718055721/http://datasheets.scbt.com/sc-25622.p df](https://web.archive.org/web/20120718055721/http://datasheets.scbt.com/sc-25622.pdf)
[retrieved on 2014-12-18]**

- **A. J. JESAITIS ET AL: "Compromised Host
Defense on Pseudomonas aeruginosa Biofilms:
Characterization of Neutrophil and Biofilm
Interactions", THE JOURNAL OF IMMUNOLOGY,
vol. 171, no. 8, 6 October 2003 (2003-10-06), pages
4329-4339, XP055141243, ISSN: 0022-1767, DOI:
10.4049/jimmunol.171.8.4329**
- **CHARLES N. SERHAN: "Novel Lipid Mediators
and Resolution Mechanisms in Acute
Inflammation", THE AMERICAN JOURNAL OF
PATHOLOGY, vol. 177, no. 4, 1 October 2010
(2010-10-01), pages 1576-1591, XP055159113,
ISSN: 0002-9440, DOI:
10.2353/ajpath.2010.100322**
- **SAGIE SCHIF-ZUCK ET AL:
"Saturated-efferocytosis generates
pro-resolving CD11b^{low} macrophages:
Modulation by resolvins and glucocorticoids",
EUROPEAN JOURNAL OF IMMUNOLOGY, vol.
41, no. 2, 29 December 2010 (2010-12-29), pages
366-379, XP055159183, ISSN: 0014-2980, DOI:
10.1002/eji.201040801**
- **THUIJLS G ET AL: "A pilot study on potential new
plasma markers for diagnosis of acute
appendicitis", AMERICAN JOURNAL OF
EMERGENCY MEDICINE, CENTRUM
PHILADELPHIA, PA, US, vol. 29, no. 3, 1 March
2011 (2011-03-01), pages 256-260, XP002691770,
ISSN: 0735-6757, DOI:
10.1016/J.AJEM.2009.09.029 [retrieved on
2010-03-25]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- G. DE LA ROSA ET AL: "Lactoferrin Acts as an Alarmin to Promote the Recruitment and Activation of APCs and Antigen-Specific Immune Responses", THE JOURNAL OF IMMUNOLOGY, vol. 180, no. 10, 3 May 2008 (2008-05-03), pages 6868-6876, XP055159178, ISSN: 0022-1767, DOI: 10.4049/jimmunol.180.10.6868
- KANYSHKOVA T G ET AL: "Lactoferrin and its biological functions", BIOCHEMISTRY, MAIK NAUKA - INTERPERIODICA, RU, vol. 66, no. 1, 1 January 2001 (2001-01-01), pages 5-13, XP002558215, ISSN: 0006-2979
- BOUMAZOU I ET AL.: 'Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin.' J. CLIN. INVEST. vol. 119, 05 January 2009, pages 20 - 32, XP002552533
- JESAITIS A.J. ET AL.: 'Compromised Host Defense on Pseudomonas aeruginosa Biofilms: Characterization of Neutrophil and BiofilmInteractions.' THE JOURNAL OF IMMUNOLOGY vol. 171, 15 October 2003, pages 4329 - 4339, XP055141243
- Ken-Ichi Komine ET AL: "FULL PAPER Internal Medicine Small Molecule Lactoferrin with an Inflammatory Effect But No Apparent Antibacterial Activity in Mastitic Mammary Gland Secretion", J. Vet. Med. Sci, 1 January 2005 (2005-01-01), pages 667-677, XP055325830, Retrieved from the Internet: URL:https://www.jstage.jst.go.jp/article/jvms/67/7/67_7_667/_pdf
- KOMINE ET AL: "Cleaved inflammatory lactoferrin peptides in parotid saliva of periodontitis patients", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 7, 26 November 2006 (2006-11-26), pages 1498-1508, XP005792680, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2006.09.003
- Yumiko Komine ET AL: "FULL PAPER Internal Medicine Inflammatory Effect of Cleaved Bovine Lactoferrin by Elastase on Staphylococcal Mastitis", J. Vet. Med. Sci, 1 January 2006 (2006-01-01), pages 715-723, XP055158837, Retrieved from the Internet: URL:https://www.jstage.jst.go.jp/article/jvms/68/7/68_7_715/_pdf [retrieved on 2014-12-16]

Description**FIELD OF THE INVENTION**

5 **[0001]** The present invention is directed to methods and kits for assessing inflammatory resolution and for distinguishing resolving and non-resolving inflammatory reactions.

BACKGROUND OF THE INVENTION

10 **[0002]** Inflammation is a biological response to injury, infection or irritation in which a cascade of cellular and microvascular reactions serves to eradicate the infection, remove damaged tissue and generate new tissue. During this process, elevated permeability in microvessels allows neutrophils and mononuclear cells to leave the intravascular compartment, and perform various anti-microbial activities to eradicate the injury. The final stage of inflammation is resolution, a process characterized by active blockade of leukocyte infiltration, followed by their apoptosis and the removal of cellular and
15 molecular debris from inflamed sites, enabling tissue to return to homeostasis.

[0003] Many inflammatory diseases fail to resolve, resulting in an excessive and potentially harmful inflammatory response. Such excessive responses are implicated in a number of common diseases such as cancer, asthma, atherosclerosis, autoimmune diseases, Alzheimer's and Parkinson's disease, among others.

20 **[0004]** A hallmark of the resolution phase is the removal of apoptotic cells, mediated by phagocytes such as macrophages and dendritic cells. In contrast to the clearance of pathogens by phagocytosis which commonly triggers an immune response, the engulfment of apoptotic cells is generally considered anti-inflammatory.

[0005] Resolution is considered a biosynthetically active process and a number of key factors and chemical mediators have been found to influence its development, including lipoxins, resolvins, protectins, maresins, eicosanoids, polyunsaturated fatty acids (PUFAs), glucocorticoids, annexin and ω -3 fatty acids, among others. Many of these mediators
25 promote resolution by stimulating macrophage uptake of apoptotic neutrophils and preventing necrosis-driven secondary inflammation.

[0006] Some of the molecular features underlying the resolution of acute inflammation have been disclosed by some of the inventors of the present invention (Bannenberg et al. J Immunol. 2005, 1;174(7):4345-55) and include specific anti-inflammatory mediators such as lipoxin, resolvins, protectins and intermediates in their generation as molecular
30 pathways of resolution.

[0007] A new population of macrophages, typically referred to as CD11b^{low} macrophages, has recently been identified by some of the inventors of the present invention (Schif-Zuck et al. Eur J Immunol. 2011 41(2):366-79). These macrophages display pro-resolving properties during the resolution of an acute inflammatory response such as increased engulfment of apoptotic leukocytes compared to other classes of macrophages, among other features.

35 **[0008]** Among the various factors found to take part in inflammatory processes is the 80 kDa glycoprotein lactoferrin. Lactoferrin belongs to the transferrin protein family, characterized by the ability to bind and transfer Fe³⁺ ions. Three different isoforms of lactoferrin have been isolated: lactoferrin- α , capable of iron binding but having no ribonuclease activity, and lactoferrin- β and γ , which possess ribonuclease activity, but are not capable of binding iron. Lactoferrin comprises a single polypeptide chain of about 700 amino acids in length folded into two globular lobes, the C - (carboxy)
40 and N - (amino) terminal regions.

[0009] The primary cells involved in lactoferrin synthesis are myeloid cells and secretory epithelia. The highest levels of lactoferrin are found in colostrums, milk and seminal plasma; lactoferrin is also found in most mucosal secretions such as uterine fluid, vaginal secretion, saliva, bile, pancreatic juice, small intestine secretions, nasal secretion, and tears. In addition, lactoferrin is found in specific granules of neutrophils, which, following degranulation, are believed to
45 be the main source of lactoferrin in blood plasma. It has been shown that lactoferrin concentration in the plasma increases during most inflammatory reactions and some viral infections (Kanyshkova et al. Biochemistry 2001, 66(1):1-7.).

[0010] Lactoferrin represents one of the first defense systems against pathogens, exhibiting antimicrobial, antibacterial, antiviral and antiparasitic activity. Lactoferrin was also found to influence immune system cells both positively and negatively. On one hand, it has been reported to support proliferation, differentiation, and activation of immune cells and
50 strengthen the immune response. On the other hand, lactoferrin has also been reported to have anti-inflammatory properties, in reducing the production of some pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF- α), interleukin 1 beta (IL-1 β) and interleukin 6 (IL-6), among others. In addition, lactoferrin has been reported to mediate inhibition of tumor growth and to possess several other biologic activities, including a ribonuclease activity (capable of RNA hydrolysis) and an osteogenic activity.

55 **[0011]** With the exception of iron binding, the biological activities of lactoferrin are thought to reside in a highly basic domain in the N-terminal region, designated lactoferricin. This part of the protein is released in the stomach at acidic pH by pepsin. Bovine lactoferricin is a highly potent 25aa peptide corresponding to residues 17-41 of lactoferrin, whereas the fragment released from human lactoferrin is larger (including positions 1-41) and has weaker antimicrobial properties.

A number of lactoferricin derivatives have been described and tested, which retain at least a part of the activities of the native domain. An antimicrobial peptide derived from ovotransferrin, called OTAP-92, has also been identified, corresponding to positions 109-200 of ovotransferrin (Vogel et al., Biochem Cell Biol. 2002; 80(1):49-63).

[0012] Japanese Patent Application Publication No. JP 2004155751 discloses a peptide capable of suppressing the production of inflammatory cytokines such as TNF- α and IL-6, wherein the peptide used may be bovine lactoferrin hydrolyzed with a protease.

[0013] U.S. Patent Application Publication No. 2007/0197426 discloses polypeptide fragments of lactoferrin comprising the amino acid sequence of phenylalanine, lysine and aspartic acid, obtained by degradation with serine proteases such as elastase, wherein the molecular weight of said fragments is preferably less than 25 kDa. Specifically, disclosed are fragments of human lactoferrin of 21-25 kDa, with N-termini located at positions 240, 288 and 341. These fragments are described as having pro-inflammatory effects, such as inducing cytokine and chemokine production. The disclosed lactoferrin fragments are said to be distinct from pro-inflammatory lactoferrin fragments having a molecular weight of 30 to 60 kDa previously identified in bovine mastitis, reported by Japanese Patent Application Publication No. JP2003/289749. US '426 further discloses the production of four short synthetic peptides corresponding to positions 243-249, 251-259, 287-293 and 295-307 of human lactoferrin, wherein two of these peptides, namely those corresponding to positions 243-249 and 295-307, demonstrated an inflammation-promoting activity.

[0014] Komine et al. (Mol Immunol. 2007 Mar;44(7):1498-508) refers to certain lactoferrin fragments identified in parotid saliva of human periodontitis patients, with N-termini located at positions 4, 238, 286 and 340 for the 32, 23, 22 and 19 kDa fragments, respectively, characterized by low Con A affinity. The amounts of these fragments in saliva were reported to increase in periodontitis in association with the severity of the clinical symptoms. It is further indicated that a longitudinal study is required to verify whether the elevated levels of these fragments subsequently decrease to the levels of healthy control subjects or whether persons who have high levels of these fragments may possess a predisposition to periodontal disease.

[0015] Komine et al. (J Vet Med Sci. 2006 Jul; 68(7):715-23) identified fragments of 38, 23, 22 and 14 kDa, generated from elastase-treated bovine lactoferrin. The publication discloses that the amino acid sequences of the 22 and 23 kDa fragments correspond to positions 237-416 and 285-449 of bovine lactoferrin, respectively. These fragments were shown to have a pro-inflammatory activity, promoting cytotoxicity and leukocyte infiltration, through induction of pro-inflammatory cytokines and chemokines (TNF- α , IL-6, IL-8 and MCP-1), and suggested to take part in the initiation or progression of inflammation. The publication further discloses that measurements of the bovine lactoferrin concentration is used in Japan as a clinical marker for bovine mastitis in lactating cows.

[0016] Certain lactoferrin fragments having low Con A affinity and have also been described by Komine et al. (J Vet Med Sci. 2006 Mar;68(3):205-11; J Vet Med Sci. 2005 Jul;67(7):667-77) in healthy or mastitic mammary gland secretions. The N-terminal positions are 237, 285 and 240 for the 23, 22 and 19 kDa fragments, respectively. It is disclosed that the concentrations of these fragments increased in mastitis in correlation to the severity of the symptoms, and decreased after antibiotic therapy. In addition, considerable fluctuations in the concentration of the low Con A affinity fragments have been detected over time in drying cows.

[0017] WO 02/39883 relates to the clinical differentiation and monitoring of gastrointestinal illnesses, more particularly to a method for aiding in differentiating irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD), and a kit usable in such method. The method is effected by determining the level of total endogenous human lactoferrin in clinical specimens, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies. WO 02/39883 further relates to a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, to monitor gastrointestinal inflammation in persons having IBD.

[0018] Jesaitis et al. (2003, J Immunol 171(8): 4329-4339) characterizes the interaction of purified human neutrophils with *P. aeruginosa*, growing in biofilms, with regard to morphology, oxygen consumption, phagocytosis, and degranulation. Jesaitis et al. suggests that lactoferrin secreted from neutrophils may be degraded by proteases (secreted at an unidentified time point and presumably during the peak of inflammation), however no specific lactoferrin fragments are identified, let alone their presence or function during resolution.

[0019] Nowhere in the background art is it taught or disclosed that lactoferrin or fragments thereof may be used as molecular markers for defining the resolution phase of inflammation. There remains an unmet need for identification of molecular signals that differentiate between resolving and non-resolving inflammation, thereby facilitating a more suitable and effective treatment to inflammatory diseases.

SUMMARY OF THE INVENTION

[0020] Disclosed herein are protein markers that appear when an inflammatory process enters a phase of resolution. The invention provides methods for diagnosing the inflammation state of a subject with an inflammatory ailment. Thus, the present invention provides methods for assessing whether a subject with an inflammation has entered the resolution phase. The invention also identifies for the first time lactoferrin fragments enabling the distinction of subjects with in-

flammation in resolution from non-resolving inflamed subjects and healthy individuals.

[0021] The present invention is based in part on the unexpected discovery that murine macrophages that have engulfed apoptotic neutrophils, degrade lactoferrin and secrete the fragments generated. It was further discovered that lactoferrin fragments of different sizes are generated during different stages of inflammation associated with *E. coli* mammary infection. Surprisingly, a novel lactoferrin fragment, having a molecular weight of about 17kDa as determined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), was identified in milk of spontaneously resolving cows following *E. coli* infection, whereas in milk from cows that did not clear the infection (i.e. did not enter the resolution phase), no such lactoferrin fragment was identified.

[0022] Kinetic analyses revealed that the levels of two other lactoferrin fragments (of 23 and 15 kDa) decreased over time until infection and inflammation were resolved, whereas the amount of the 17 kDa fragment increased over time in resolving cows. In contrast, in non-resolving cows, appearance of the 23 kDa fragment was very late compared to resolving cows and the levels of the smaller fragments were very low, whereas in milk obtained from healthy cows, lactoferrin and its fragments were barely detectable. The amount of the 17kDa fragment, as well as the relative quantities of lactoferrin fragments, advantageously expressed as the ratio between the amounts of the 23 and 17 kDa fragments in a sample, have thus been unexpectedly identified as diagnostic markers for transition from inflammation to resolution.

[0023] These findings were further validated in an *in vivo* murine peritonitis model, in which Lactoferrin fragments were surprisingly found to be released to the interstitial space in spleen and inguinal lymph nodes. Six distinguishable fragments of 50, 37, 23, 21, 17 and 15 kDa (as evaluated by SDS-PAGE), were detectable in addition to the full length 78 kDa protein. The 17kDa fragment was unexpectedly identified as a common marker for resolving inflammation, as the amount of this fragment consistently increased during resolution in both splenic and lymph node fluids.

[0024] Thus, the presence or amounts of isolated lactoferrin fragments obtained from inflammatory tissues or secretory fluids of a subject reflects whether the subject has begun clinical recovery or not. The methods of the invention may hence be used for determining whether to apply a treatment to a subject, thereby saving unnecessary, expensive and potentially harmful treatments from subjects who have already entered the recovery track.

[0025] Accordingly, in general there are disclosed methods for assessing the presence or absence of inflammation in resolution in a subject, comprising determining the molecular weight of at least one lactoferrin fragment in a sample obtained from the subject.

[0026] According to a first aspect of the present invention, there is provided a method for assessing resolution of inflammation in a subject, comprising determining the presence of a lactoferrin fragment characteristic of resolution having a molecular weight of about 17 kDa in a sample obtained from an inflammatory tissue or from body fluids of the subject, and quantifying the amount of the lactoferrin fragment in the sample, wherein the presence of said fragment in said sample, in an amount significantly higher than its amount in a control sample corresponding to a subject having non-resolving inflammation and/or a healthy subject, indicates that said subject has inflammation in resolution, wherein said fragment comprises an amino acid sequence corresponding to positions 172-342 of mammalian lactoferrin, or wherein the fragment characteristic of resolution having a molecular weight of about 17 kDa comprises at least one of SEQ ID NOs: 7-10.

[0027] According to some embodiments, the fragment characteristic of resolution, useful as a diagnostic marker in the methods of the invention, comprises an amino acid sequence corresponding to positions 172-342 of mammalian lactoferrin, for example bovine lactoferrin (e.g. positions 172-342 of SEQ ID NO: 5) or human lactoferrin (e.g. positions 172-342 of SEQ ID NO: 6).

[0028] According to yet another embodiment, the method further comprises quantifying the amounts of the lactoferrin fragments in said sample, and determining the ratio of the amount of the lactoferrin fragment characteristic of resolution (having a molecular weight of about 17 kDa) to the amount of a lactoferrin fragment having a molecular weight of about 15 kDa, wherein said fragments comprise an amino acid sequence corresponding to positions 172-342 and 20-182 of mammalian lactoferrin, respectively, and wherein a ratio significantly higher than determined for a control sample corresponding to a subject having non-resolving inflammation indicates that said subject has inflammation in resolution. According to yet another embodiment, a ratio of at least 3 indicates that said subject has inflammation in resolution.

[0029] According to another aspect, the present method is for monitoring the progression of inflammatory resolution in a subject in need thereof, and further comprises determining the amount of the lactoferrin fragment having a molecular weight of about 17 kDa in a first sample obtained from the subject at a first time point, and in a second sample obtained from said subject at a second subsequent time point, wherein an increase in the amount of said fragment in said second sample compared to said first sample indicates a positive progression in inflammatory resolution.

[0030] Specifically, provided is a method for determining whether a subject having an inflammatory disease is a candidate for a treatment for the disease, comprising assessing the resolution of inflammation in the subject by determining the presence of a lactoferrin fragment characteristic of resolution having a molecular weight of about 17 kDa in a sample obtained from said subject, wherein the presence of the fragment in said sample indicates that said subject has inflammation in resolution and the absence of resolution indicates that said subject is a candidate for the treatment, wherein said fragment comprises an amino acid sequence corresponding to positions 172-342 of mammalian lactoferrin,

or wherein the fragment characteristic of resolution has a molecular weight of about 17 kDa comprises at least one of SEQ ID NOs: 7-10.

[0031] According to yet another embodiment of the methods of the invention, the subject is selected from humans and non-human mammals. In another embodiment the subject is human. In another embodiment the subject is selected from livestock and domestic animals. According to yet another embodiment the subject is a lactating mammal. According to yet another embodiment the subject is bovine.

[0032] In another embodiment the inflammatory disease is associated with an infection, e.g. a bacterial infection, viral infection, fungal infection or parasitic infection. According to a particular embodiment the inflammatory disease is associated with *E. coli* infection. In another embodiment the inflammatory disease is mastitis (e.g. *E. coli* induced mastitis). In another embodiment the inflammatory disease is peritonitis.

[0033] The sample can be obtained from an inflammatory tissue or from body fluids of the subject. The samples may be obtained from e.g. milk, blood, urine and lymph samples, or from other mucosal secretions (e.g. uterine fluid, vaginal secretion, saliva, bile, pancreatic juice, small intestine secretions, nasal secretion, colostrums and tears). The sample can be obtained in a noninvasive manner (e.g. milk samples, urine samples or saliva samples). The sample can be separated (e.g. by centrifugation) to a cell-enriched fraction (cellular fraction) and a substantially cell-free fraction (soluble fraction). The molecular weight of the lactoferrin fragments (or their presence or amount) can be determined in the cellular fraction of the sample. The molecular weight of the lactoferrin fragments (or their presence or amount) can also be determined in the soluble fraction of the sample. The subject can be a lactating mammal (e.g. a lactating cattle) and the sample can be a milk sample.

[0034] Determining the molecular weight (or the presence or amount) of lactoferrin fragments can be performed by a method comprising an immunoassay (e.g. molecular weight separation by gel electrophoresis and Western blot analysis using lactoferrin-specific antibodies).

[0035] According to other embodiments, the lactoferrin fragment having a molecular weight of about 17 kDa, identified as a fragment characteristic of resolution useful as a diagnostic marker in the methods of the invention, comprises at least one (and preferably 2, 3 or 4) of SEQ ID NOs: 7-10. According to another embodiment, said fragment comprises SEQ ID NOs: 7-10. Said fragment can be further characterized in that it does not contain at least one (and preferably 2-8) or all of SEQ ID NOs: 11-18.

[0036] In a particular embodiment the lactoferrin is bovine lactoferrin and said fragment has an amino acid sequence as set forth in SEQ ID NO: 1.

[0037] In another particular embodiment the lactoferrin is human lactoferrin and said fragment has an amino acid sequence as set forth in SEQ ID NO: 2.

[0038] The lactoferrin fragment having a molecular weight of about 15 kDa disclosed herein comprises at least one (and preferably 2-8 or all) of SEQ ID NOs: 10-18. Said fragment may be further characterized in that it does not contain at least one (and preferably 2-4) or all of SEQ ID NOs: 7-9.

[0039] Also disclosed is an isolated lactoferrin fragment characteristic of resolution having a molecular weight of about 17kDa, the fragment having an amino acid sequence as set forth in any one of SEQ ID NOs: 1 and 2 or at least 90% amino acid identity thereto. The fragment can be selected from the group consisting of SEQ ID NOs: 1 and 2.

[0040] There is also disclosed an isolated lactoferrin fragment having a molecular weight of about 15kDa, the fragment having an amino acid sequence as set forth in any one of SEQ ID NOs: 3 and 4 or at least 90% amino acid identity thereto. The fragment can be selected from the group consisting of SEQ ID NOs: 3 and 4.

[0041] In another aspect there is provided a kit for assessing the presence or absence of resolving inflammation in a subject, comprising means for determining the presence of a lactoferrin fragment characteristic of resolution having a molecular weight of about 17 kDa in a sample; wherein the means comprise an antibody specifically recognizing an isolated lactoferrin fragment characteristic of resolution having a molecular weight of about 17kDa, the fragment having an amino acid sequence as set forth in any one of SEQ ID NOs: 1 and 2, wherein binding of the antibody to said fragment is not competitively inhibited by the presence of an isolated lactoferrin fragment having an amino acid sequence as set forth in any one of SEQ ID NOs: 3 and 4, the kit further comprising one or more isolated lactoferrin fragments selected from the group consisting of:

- a. An isolated lactoferrin fragment characteristic of resolution having a molecular weight of about 17kDa, the fragment having an amino acid sequence as set forth in any one of SEQ ID NOs: 1 and 2 or at least 90% amino acid identity thereto; and
- b. An isolated lactoferrin fragment having a molecular weight of about 15kDa, the fragment having an amino acid sequence as set forth in any one of SEQ ID NOs: 3 and 4 or at least 90% amino acid identity thereto.

[0042] Further aspects and embodiments of the present invention are disclosed in the accompanying claims.

[0043] Further embodiments, features, advantages and the full scope of applicability of the present invention will become apparent from the detailed description and drawings given hereinafter.

BRIEF DESCRIPTION OF THE DRAWINGS

[0044]

FIG. 1 Shows lactoferrin fragments obtained from macrophages (lane 1), macrophages incubated with apoptotic Jurkat cells (lane 2), apoptotic neutrophils (lane 3) and macrophages incubated with apoptotic neutrophils (lane 4).

FIG. 2 Shows lactoferrin fragments obtained from milk of healthy or *E. coli* infected cows.

FIG2A shows lactoferrin fragments obtained from cellular and soluble milk fractions in resolving cows at the indicated time points after infection. **FIG2B** shows lactoferrin fragments obtained from cellular and soluble milk fractions in non-resolving cows at the indicated time points after infection and of lactoferrin fragments obtained from healthy cows ("Healthy").

FIG. 3 Shows Lactoferrin fragments in interstitial fluids of spleen and inguinal lymph node during peritonitis. Spleen and inguinal lymph nodes were harvested 24 and 66 hrs after peritonitis initiation (n=9) and mashed. Equal amounts of interstitial fluid protein were run by 10% SDS PAGE, followed by Western blotting for Lactoferrin. The results demonstrate six different Lactoferrin-derived fragments: 50, 37, 23, 21, 17, and 15 kDa, in addition to the full length 78 kDa Lactoferrin. Results of representative blots from spleen and inguinal lymph nodes (A, C respectively) and average densitometric analysis (B, D respectively) are shown. * p value<0.05, ** p value<0.005, *** p value<0.001.

FIG. 4 Shows isolation of bovine Lactoferrin and its derived fragments from mastitis-inflicted cows. Milk samples were collected at day 3 (left) or day 5 (right) from the onset of infection and protein samples were eluted from a heparin affinity column at the indicated salt concentrations. Products were assessed by SDS-PAGE and Western blotting using secondary antibody only (FIG. 4A) or anti-lactoferrin sera and secondary antibody (FIG. 4B). Arrows indicate the locations of the 15 and 17kDa lactoferrin fragments isolated from the gel following electrophoresis and subjected to sequencing.

DETAILED DESCRIPTION OF THE INVENTION

[0045] The present invention is directed to methods and kits for assessing resolution of inflammation in a subject. Also disclosed are methods for determining whether a subject having an inflammatory disease is a candidate for a treatment for the disease, comprising assessing the resolution of inflammation in the subject.

[0046] "Resolution of inflammation", "inflammatory resolution" and "resolution" are used herein interchangeably and refer to an active process controlled by endogenous 'pro-resolving' mediators, which terminates an inflammatory reaction and leads to the restoration of the inflamed tissue to its prior physiological function. Endogenous mediators controlling this process may limit leukocyte trafficking to the inflamed site, reverse vasodilation and vascular permeability, and/or promote the removal of inflammatory leukocytes, exudate and fibrin. The terms "inflammation in resolution" and "resolving inflammation" as used herein indicate the clinical state of a subject with inflammation undergoing resolution. Typically, resolving inflammation indicates an inflammatory state in which at least 50% of the leukocytes infiltrating the inflammatory site are macrophages. Resolving inflammation may correspond to the period between maximal infiltration of polymorphonuclear cells (PMN) to the inflamed site and complete remission of inflammation. Thus, subjects with inflammation in resolution are distinguished from healthy subjects in which complete remission has been accomplished, as well as from subjects in which the inflammatory process is increasing or is in steady state. In a subject with inflammation in resolution the pathogen or inducer of inflammation may have been cleared from the inflammatory site; however, some inflammatory processes may still progress in the absence of the inducing pathogen.

[0047] As used herein, "positive progression of resolution" means enhancement or augmentation of the resolution process as described herein, leading to reduction or subsequent termination of the inflammatory process. Positive progression of resolution is typically associated with a positive outcome of the inflammatory disease or condition.

[0048] According to a first aspect of the present invention, there is provided a method for assessing resolution of inflammation in a subject as disclosed in claim 1. In another aspect, there is provided a method for determining whether a subject having an inflammatory disease is a candidate for a treatment for the disease, as disclosed in claim 10. In another aspect, there is provided a kit as defined in claim 12.

[0049] The term "about" as used herein means approximately, roughly or around of, typically extending the boundaries 10% above and below the numerical values set forth. Thus, for example, "about 17 kDa" means 16-19 kDa and "about 23 kDa" means 21-24 kDa.

[0050] The molecular weight of said fragment can be essentially 17 kDa. The term essentially as used herein with reference to a molecular weight typically means up to 0.5 kDa above or below the molecular weight set forth. The

molecular weight of said fragment can be 17 kDa

[0051] The lactoferrin fragment characteristic of resolution can be produced by macrophages following incubation with apoptotic neutrophils (e.g. following ex vivo incubation for 24 hrs at a macrophage:neutrophil ratio of at least 1:5). Said fragment can be produced by CD11b^{low} macrophages, characterized by surface expression of CD11b which is about 5-10 times lower than its mean surface expression on inflammatory peritoneal macrophages.

[0052] A "control sample corresponding to a subject" may refer to a sample obtained from a subject, a combined sample obtained from a pool of subjects, or a pre-stored reference value (e.g. in a sample obtained from a subject, or the mean value in a combined sample obtained from a pool of subjects).

[0053] The method may further comprise quantifying the amounts of two or more lactoferrin fragments having different molecular weights in said sample and determining the amount ratio of the fragments. The method may further comprise comparing said ratio to that of fragments in control samples corresponding to subjects having resolving inflammation, non-resolving inflammation and/or healthy subjects. The methods of the invention can be suitable for monitoring the progression of inflammation in a subject in need thereof

Subjects, diseases and samples

[0054] In the methods of the invention, the subject can be suspected of having an inflammatory disease, or the subject is diagnosed with an inflammatory disease.

[0055] According to yet another embodiment the subject is selected from humans and non-human mammals. In another embodiment the subject is human. The subject can be selected from livestock and domestic animals. The subject can also be a dairy animal (e.g. bovine or ovine). According to another embodiment the subject is a lactating mammal. According to yet another embodiment the subject is bovine.

[0056] The term "livestock animals" as used herein refers to domesticated quadrupeds, which includes those being raised for meat and various byproducts, e.g., a bovine animal including cattle and other members of the genus *Bos*, a porcine animal including domestic swine and other members of the genus *Sus*, an ovine animal including sheep and other members of the genus *Ovis*, domestic goats and other members of the genus *Capra*; domesticated quadrupeds being raised for specialized tasks such as use as a beast of burden, e.g., an equine animal including domestic horses and other members of the family Equidae, genus *Equus*, or for searching and sentinel duty.

[0057] The term "domestic animals" includes mammals such as e.g., a canine animal including domestic dogs and other members of the genus *Canis*; and domesticated quadrupeds being raised primarily for recreational purposes, e.g., members of *Equus* and *Canis*, as well as a feline animal including domestic cats and other members of the family Felidae, genus *Felis*.

[0058] The inflammatory disease can be an autoimmune disease (e.g. systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (Crohn's disease, ulcerative colitis) and autoimmune hepatitis). In another embodiment the inflammatory disease is associated with an infection. For example, the inflammatory disease may be associated with a bacterial infection, viral infection (e.g. influenza, West Nile virus) fungal infection or parasitic infection. According to a particular embodiment the inflammatory disease is associated with *E. coli* infection. In another embodiment the inflammatory disease is mastitis (e.g. *E. coli* induced mastitis). In another embodiment the disease is peritonitis. However, the disease may be associated with various other primary or secondary infections, e.g. chronic obstructive pulmonary disease (COPD), chronic granulomatous disease (CGD) or hepatitis.

[0059] As used herein the term "mastitis" refers to an inflammation of a mammary gland or an udder. Mastitis is most commonly caused by bacterial invasion and their toxins. It has been described in humans, cows, sheep, goats, pigs, horses, and rabbits. Mastitis causes lactating women to experience pain when nursing the child, it damages mammary tissue, and the formation of scar tissue in the breast may cause disfigurement. In dairy cattle, mastitis is believed to be the most economically important disease.

[0060] In subclinical mastitis, no swelling of the breast or udder is detected nor are there observable abnormalities in the milk. Special screening tests, however, such as the California Mastitis Test (CMT), Wisconsin Mastitis Test (WMT) based on an estimation of somatic cell counts and the catalase test will show changes in the milk composition. This type of mastitis is commonly referred to as "hidden".

[0061] Clinical mastitis can be mild or acute, and is characterized by the presence of leukocytes in the milk. Mild clinical mastitis involves changes in the milk appearance including presence of flakes or clots, watery milk or other unusual forms of the milk. Mild clinical mastitis may be accompanied by other symptoms including hot, sensitive or swollen breast or udder.

[0062] Severe clinical mastitis involves the symptoms of hot, sensitive, firm breast or udder that is quite painful to the lactating animal. The onset of severe clinical mastitis is sudden and the lactating animal may become ill showing signs of fever, rapid pulse, depression, weakness and loss of appetite. When the whole lactation system of the animal is affected, the condition is referred to as acute systemic mastitis. The severe symptoms may be also accompanied with cessation of milk production.

[0063] Chronic mastitis is persistent udder infection, typically in the form of subclinical mastitis, which occasionally can develop into the clinical form and back to the subclinical form. Chronic mastitis is characterized by hard lump within the mammary gland due to the establishment of bacteria and the formation of connective tissue.

[0064] Mastitis can be caused by bacteria; for example, bovine mastitis may be caused primarily by bacteria and/or may be caused by yeasts and molds. In some cases the causes of bovine mastitis are unknown and could be due to physical trauma or weather extremes. Although bovine mastitis can be caused by many different bacterial species, the most common are the *Staphylococcus* and *Streptococcus* species. The most common staphylococci and streptococci causing bovine mastitis include *Staphylococcus aureus*, *Streptococcus dysgalactiae*, *Streptococcus equinus*, *Streptococcus agalactiae*, *Staphylococcus hyicus*, *Staphylococcus simulans*, *Staphylococcus epidermidis*, *Staphylococcus chromogenes* and *Staphylococcus xylosus*. Other staphylococci and streptococci known to cause bovine mastitis include *Staphylococcus Oxford*, *Staphylococcus aureus* WCUH29, *Streptococcus pneumoniae* ERY2, *Streptococcus pneumoniae* 1629, *Streptococcus pneumoniae* N 1387, *Enterococcus faecalis* I, *Enterococcus faecalis* 7, *Haemophilus influenzae* QI, *Haemophilus influenzae* NEMC1, *Moraxella Catarrhalis* 1502, *Escherichia coli* 7623 AcrABEFD+, *Escherichia coli* 120 AcrAB-, *Escherichia coli* MG1655, or *Escherichia coli* MG1658. The organism may be methicillin-resistant *Staphylococcus aureus*.

[0065] Bovine mastitis may also be caused by gram-negative bacteria, or by organisms such as *Pseudomonas aeruginosa*, *Brucella melitensis*, *Corynebacterium bovis*, various species of *Mycoplasma*, *Escherichia coli*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, *Enterobacter aerogenes*, various species of *Pasteurella*, *Arcanobacterium pyogenes*, various species of *Proteus*, *Prototheca zopfii* (e.g., achlorophyllic algae), and *Prototheca wickerhamii* (e.g., achlorophyllic algae).

[0066] Examples 2 and 4 herein demonstrate detection of a fragment of about 17 kDa as assessed by SDS-PAGE, in milk samples obtained from cows resolving from clinical mastitis induced by or associated with infection of *E. coli* (Example 2) or various pathogens (Example 4).

[0067] Treatment of the affected animal includes antibiotics (e.g. by intramammary injections) to eliminate the respective bacteria, and anti-inflammatory agents to reduce swelling.

[0068] For example, intramammary dry cow therapy reduces the number of contagious infections during the dry period and environmental streptococcal infections during the early dry period. The dry cow preparations are formulated (vehicles, solvents, pH) to cause minimal tissue irritation, to avoid damaging the secretory tissue and to prevent fibrosis. An antibiotic which is active against Gram-positive organisms in low concentrations is chosen, and if combinations are used, antibiotics with bactericidal effects are preferable. Antibiotic combinations of cloxacillin, ampicillin, cephapirin, streptomycin, cephalixin, penethamate, erythromycin, amoxicillin, penicillin, nafcillin are frequently used, according to acceptable protocols.

[0069] Antibiotic treatment of subclinical mastitis during lactation is cost effective and increases the opportunities for drug residues in milk. According to the Food and Drug Administration/ Center for Veterinary Medicine the approved antibiotics for the treatment of bovine mastitis are: pirlimycin, methicillin, cloxacillin, amoxicillin, novobiocin, penicillin G, dihydrostreptomycin, cephapirin and erythromycin. The choice of the antimicrobial agents and the route of administration is directed by the characteristics of the drug and regulatory issues. Many antimicrobial drugs used for mastitis treatment, including compounds that penetrate the mammary gland, are sulfonamides, penicillins with the exception of penethamate iodide, aminoglycosides, and early-generation cephalosporins.

[0070] Peritonitis is inflammation of the peritoneal cavity. The most serious cause is perforation of the GI tract, which causes immediate chemical inflammation followed shortly by infection from intestinal organisms. Peritonitis can also result from any abdominal condition that causes marked inflammation (e.g., appendicitis, diverticulitis, strangulating intestinal obstruction, pancreatitis, pelvic inflammatory disease, mesenteric ischemia). Intraperitoneal blood from any source (e.g., ruptured aneurysm, trauma, surgery, ectopic pregnancy) is irritating and results in peritonitis. Peritoneo-systemic shunts, drains, and dialysis catheters in the peritoneal cavity predispose a patient to infectious peritonitis, as does ascitic fluid. Spontaneous bacterial peritonitis may occur, in which the peritoneal cavity is infected by blood-borne bacteria.

[0071] Peritonitis causes fluid shift into the peritoneal cavity and bowel, leading to severe dehydration and electrolyte disturbances. Adult respiratory distress syndrome can develop rapidly, with following kidney failure, liver failure, and disseminated intravascular coagulation.

[0072] Infectious peritonitis can be classified as primary, secondary, or tertiary. In primary peritonitis (also called spontaneous bacterial peritonitis), the source of infection does not arise from the gastrointestinal tract, and there is no identifiable anatomical derangement of the intra-abdominal viscera. Primary peritonitis is mostly caused by a chronic liver disease, such as cirrhosis. In contrast, secondary peritonitis is due to an infection of the abdominal viscera, and may arise as a consequence of perforation, ischemic necrosis, or penetrating injury. Tertiary peritonitis is defined as peritonitis that persists or recurs after more than one failed source control procedure, and is highly frequent in patients requiring intensive care unit admission for severe abdominal infections. The most common organisms implicated in bacterial peritonitis are *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *C. perfringens*, *Neisseria gonorrhea*, *Chlamydia trachomatis*, *Mycobacterium tuberculosis*, *Chlamydia trachomatis*, *Clostridium perfringens*, strep-

tococci and enterococci. The most common fungal agents to cause infectious peritonitis are *Candida albicans*, *Candida parapsilosis*, and *Aspergillus fumigatus*. Such infections are treated by the respective antibiotics or other anti-bacterial or antifungal agent, as known in the art.

[0073] For instance Example 3 demonstrates detection of a 17kDa lactoferrin fragment in spleen and lymph node interstitial fluids during resolution in a mouse peritonitis model. Example 1 demonstrates that murine macrophages characteristic of resolving peritonitis are capable of acquiring lactoferrin from apoptotic PMN and degrading it to smaller fragments, wherein Example 3 demonstrates that a 17kDa lactoferrin fragment is eventually released at the spleen and lymph node.

[0074] The sample can be obtained from an inflammatory tissue or from body fluids of the subject. The lactoferrin fragments may be obtained from fluid samples, including but not limited to milk (or mammary secretions), blood, urine and lymph samples, and samples obtained from other mucosal secretions (e.g. uterine fluid, vaginal secretion, saliva, bile, pancreatic juice, small intestine secretions, nasal secretion, colostrums and tears). The sample can be obtained in a noninvasive manner (e.g. milk samples, urine samples saliva samples). The sample can be separated (e.g. by centrifugation) to a cell-enriched fraction (cellular fraction) and a substantially cell-free fraction (soluble fraction). The molecular weight of the lactoferrin fragments (or their presence or amount) can be determined in the cellular fraction of the sample. The molecular weight of the lactoferrin fragments (or their presence or amount) can also be determined in the soluble fraction of the sample. The subject can be a lactating mammal (e.g. a lactating cattle) and the sample can be a milk sample. Tissue or fluid samples to be used in the methods of the invention may be obtained and optionally further purified, diluted or otherwise processed using methods well known in the art. Non-limitative examples for obtaining, purifying and processing various biological samples are presented in the Examples section herein.

Diagnostic methods and means

[0075] Determining the molecular weight of lactoferrin (and/or detecting the presence or amount of specific lactoferrin fragments) can be performed by an immunoassay. By means of a nonlimiting example, the methods of the invention may involve molecular weight separation by gel electrophoresis and Western blot analysis using lactoferrin-specific antibodies. Various other immunoassays may be utilized, e.g. Enzyme-linked immunosorbent assay (ELISA) using antibodies directed to specific lactoferrin fragments (capable of specifically binding and differentiating between different fragments) or assays based on dipstick technology or antibody array. The methods of the invention are suitable for automated or semi-automated analysis, and may enable clinical, medium or high-throughput screening of multiple samples. For example, automated ELISA systems such as Biotest's Quickstep® ELISA Processor, Maxmat Automated microwell ELISA analyzer (Maxmat S.A., France), or DSX™ Four-Plate System (Dynex Technologies) may conveniently be used. Such techniques are well known to the ordinarily skilled artisan and have been described in many standard immunology manuals and texts.

[0076] For instance, Examples 1-4 herein demonstrate detection of lactoferrin fragments and evaluation of their molecular weight gel separation using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 7-10%, transfer to a nitrocellulose membrane and blotting using an anti-lactoferrin polyclonal IgG (sc-25622, Santa Cruz Biotechnology) and labeled secondary antibody. As demonstrated in these examples, the lactoferrin fragment characteristic of resolution was determined by this method to be of about 17 kDa. Although the presence of detergents such as SDS act to denature the polypeptides and equalize their charges such that their migration rate should be proportional to their size and independent of other factors such as shape and charge, it is noted, that certain polypeptides may still be influenced by these additional factors during SDS-PAGE separation. Thus, for example, a polypeptide evaluated as having a molecular weight of 17 kDa using SDS-PAGE separation may be up to 10% longer or shorter as determined by sequence analysis.

[0077] Evaluating the molecular weight of lactoferrin fragments by gel electrophoresis may be performed in 7-10% SDS-PAGE in the presence of 1-3% SDS, at 80-120V e.g. 80V for 30 minutes for upper gel and 120V for 90 minutes for lower gel. Samples may be boiled e.g. for 5 min in sample buffer which may contain in one example (for sample buffer x2) 150mM Tris pH 6.8, 20% glycerol, 4% SDS, 5% β-mercaptoethanol, and 15ug/ml bromophenol blue. Variations and modifications to the example and parameters may be made by the skilled artisan to adjust the assay as required.

[0078] In another aspect, there is provided a kit for assessing the presence or absence of resolving inflammation in a subject, comprising means for determining the presence of a lactoferrin fragment characteristic of resolution, as described herein and as disclosed in accompanying claim 12. For example, the kit may comprise one or more lactoferrin-specific antibodies and/or reference samples comprising one or more lactoferrin fragments (e.g. the fragments having an amino acid sequence as set forth in SEQ ID NOs: 1-4).

[0079] The kit further comprises one or more isolated lactoferrin fragments, selected from:

an isolated fragment characteristic of resolution having a molecular weight of about 17kDa, the fragment having an amino acid sequence as set forth in any one of SEQ ID NOs: 1 and 2 or at least 90% amino acid identity thereto, and

an isolated lactoferrin fragment having a molecular weight of about 15kDa, the fragment having an amino acid sequence as set forth in any one of SEQ ID NOS: 3 and 4 or at least 90% amino acid identity thereto.

[0080] The kit may further comprise instructions for diagnosing resolving inflammation, wherein the presence of said fragment in said sample, e.g. in an amount significantly higher than its amount in a control sample corresponding to a subject having non-resolving inflammation and/or a healthy subject, indicates that said subject has inflammation in resolution.

[0081] Also disclosed is an antibody specifically recognizing an isolated lactoferrin fragment characteristic of resolution having a molecular weight of about 17kDa, the fragment having an amino acid sequence as set forth in any one of SEQ ID NOS: 1 and 2.

[0082] The terms "antibody" or "antibodies" as used herein refer to an antibody or fragments thereof, including, but not limited to, a full length antibody having a human immunoglobulin constant region, a monoclonal IgG, a single chain antibody, a humanized monoclonal antibody, an F(ab')₂ fragment, an F(ab) fragment, an Fv fragment, a labeled antibody, an immobilized antibody and an antibody conjugated with a heterologous compound. The antibody can be a monoclonal antibody or a polyclonal antibody. The antibody can also be a humanized antibody.

[0083] Methods of generating monoclonal and polyclonal antibodies are well known in the art. Antibodies may be generated via any one of several known methods, which may employ induction of *in vivo* production of antibody molecules, screening of immunoglobulin libraries, or generation of monoclonal antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the Epstein-Barr virus (EBV)-hybridoma technique. Besides the conventional method of raising antibodies *in vivo*, antibodies can be generated *in vitro* using phage display technology, by methods well known in the art (e.g. Current Protocols in Immunology, Colligan et al (Eds.), John Wiley & Sons, Inc. (1992-2000), Chapter 17, Section 17.1).

[0084] An antigen (e.g. a lactoferrin fragment) or immunogenic complex (e.g. an epitope specific to said fragment conjugated to a protein carrier such as BSA) can be injected into suitable mammalian subjects such as mice, rabbits, and others. Suitable protocols involve repeated injection of the immunogen in the presence of adjuvants according to a schedule designed to boost production of antibodies in the serum. The titers of the immune serum can readily be measured using immunoassay procedures which are well known in the art. The antisera obtained can be used directly (e.g. as diluted sera or as purified polyclonal antibodies), or monoclonal antibodies may be obtained, as described herein.

[0085] A monoclonal antibody (mAb) is a substantially homogeneous population of antibodies to a specific antigen. mAbs may be obtained by methods known to those skilled in the art. See, for example US patent 4,376,110; Ausubel et al ("Current Protocols in Molecular Biology," Volumes I-III, John Wiley & Sons, Baltimore, Maryland, 1994). A hybridoma producing a mAb may be cultivated *in vitro* or *in vivo*. High titers of mAbs can be obtained in *in vivo* production where cells from the individual hybridomas are injected intraperitoneally into pristine-primed Balb/c mice to produce ascites fluid containing high concentrations of the desired mAbs. mAbs of isotype IgM or IgG may be purified from such ascites fluids, or from culture supernatants, using column chromatography methods well known to those of skill in the art.

[0086] Antibody fragments may be obtained using methods well known in the art. (See, for example, Harlow, E. and Lane, D. (1988). Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). For example, antibody fragments can be prepared by proteolytic hydrolysis of the antibody or by expression in *E. coli* or mammalian cells (e.g., Chinese hamster ovary (CHO) cell culture or other protein expression systems) of DNA encoding the fragment.

[0087] Alternatively, antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. As described hereinabove, F(ab')₂ antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly. Ample guidance for practicing such methods is provided in the literature of the art (for example, refer to: U.S. Pat. Nos. 4,036,945 and 4,331,647). Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments retain the ability to bind to the antigen that is recognized by the intact antibody.

[0088] An Fv is composed of paired heavy chain variable and light chain variable domains. This association may be noncovalent. Alternatively, as described hereinabove, the variable domains may be linked to generate a single-chain Fv by an intermolecular disulfide bond, or alternately such chains may be cross-linked by chemicals such as glutaraldehyde.

[0089] Preferably, the Fv is a single-chain Fv. Single-chain Fvs are prepared by constructing a structural gene comprising DNA sequences encoding the heavy chain variable and light chain variable domains connected by an oligonucleotide encoding a peptide linker. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two variable domains. Ample guidance for producing single-chain Fvs is provided in the literature

of the art. Improved bivalent miniantibodies, with identical avidity as whole antibodies, may be produced by high cell density fermentation of *Escherichia coli*. (U.S. Pat. No. 4,946,778).

[0090] After antibodies have been obtained, they may be tested for activity, for example via enzyme-linked immunosorbent assay (ELISA).

[0091] The antibodies may specifically bind to a lactoferrin fragment (e.g. a fragment of about 17 kDa characteristic of resolution as described herein). The terms "specific binding" or "specifically binds" refers to two molecules forming a complex that is relatively stable under physiologic conditions. Specific binding is characterized by a high affinity and a low to moderate capacity as distinguished from nonspecific binding which usually has a low affinity with a moderate to high capacity. Typically, binding is considered specific when the association constant K_A is higher than 10^6 M^{-1} . If necessary, nonspecific binding can be reduced without substantially affecting specific binding by varying the binding conditions. The appropriate binding conditions, such as concentration of antibodies, ionic strength of the solution, temperature, time allowed for binding, concentration of a blocking agent (e.g., serum albumin, milk casein), etc., may be optimized by a skilled artisan using routine techniques. The term "specifically recognizing" further indicate that the binding of an antibody to an antigen is not competitively inhibited by the presence of non-related molecules (e.g. other lactoferrin fragments as described herein). Conveniently, detection of the capacity of an antibody to specifically bind an antigen, e.g. a lactoferrin fragment, may be performed by quantifying specific antigen-antibody complex formation (e.g. by ELISA).

[0092] Identifying an appropriate epitope useful for raising antibodies specific to the fragment characteristic of resolution is within the abilities of those skilled in the art. As the respective amino acid positions of this fragment and other lactoferrin fragments are set forth herein or are known in the art, one of skill in the art would be able to choose a region within the fragment of about 17 kDa which does not overlap with the fragment of about 15 kDa, or other fragments identified in the art.

[0093] In another aspect, there is provided a method for assessing resolution of inflammation in a subject, comprising determining the presence of a lactoferrin fragment characteristic of resolution having a molecular weight of about 17 kDa in a sample obtained from an inflammatory tissue or from body fluids of the subject, and quantifying the amount of the lactoferrin fragment in the sample, wherein the presence of said fragment in said sample, in an amount significantly higher than its amount in a control sample corresponding to a subject having non-resolving inflammation and/or a healthy subject, indicates that said subject has inflammation in resolution, wherein said fragment comprises an amino acid sequence corresponding to positions 172-342 of mammalian lactoferrin, or wherein the fragment characteristic of resolution having a molecular weight of about 17 kDa comprises at least one of SEQ ID NOs: 7-10.

[0094] In another embodiment, said fragment comprises an amino acid sequence corresponding to positions 172-342 of human or bovine lactoferrin; or the fragment characteristic of resolution having a molecular weight of about 17 kDa comprises SEQ ID NOs: 7-10.

[0095] In another embodiment, the method further comprises quantifying the amounts of lactoferrin fragments in said sample, and determining the ratio of the amount of the lactoferrin fragment characteristic of resolution to the amount of a lactoferrin fragment having a molecular weight of about 15 kDa, wherein said fragments comprise an amino acid sequence corresponding to positions 172-342 and 20-182 of mammalian lactoferrin, respectively, and wherein a ratio significantly higher than that determined for a control sample corresponding to a subject having non-resolving inflammation indicates that said subject has inflammation in resolution, preferably wherein a ratio of at least 3 indicates that said subject has inflammation in resolution.

[0096] In another embodiment, the sample is obtained from body fluids selected from the group consisting of milk, blood, urine and lymph samples, and samples obtained from uterine fluid, vaginal secretion, saliva, bile, pancreatic juice, small intestine secretions, nasal secretion, colostrums and tears, preferably the sample is a milk sample.

[0097] In another embodiment, the method is for monitoring the progression of inflammatory resolution in a subject in need thereof, and further comprises determining the amount of the lactoferrin fragment characteristic of resolution having a molecular weight of about 17 kDa in a first sample obtained from the subject at a first time point, and in a second sample obtained from said subject at a second subsequent time point, wherein an increase in the amount of said fragment in the second sample compared to the first sample indicates a positive progression of inflammatory resolution.

[0098] In another embodiment, said fragment comprises an amino acid sequence corresponding to positions 172-342 of human or bovine lactoferrin, preferably wherein said fragment has an amino acid sequence as set forth in SEQ ID NO: 1 or in SEQ ID NO: 2.

[0099] In another embodiment, the subject is selected from humans and non-human mammals, preferably the subject is human or bovine or a lactating mammal.

[0100] In another embodiment, the inflammation is associated with an infection. In various embodiments, the infection is a bacterial infection, a viral infection, a fungal infection or a parasitic infection, preferably associated with *E. coli* infection, more preferably with mastitis; or the inflammation may be associated with peritonitis.

[0101] In another aspect, there is provided a method for determining whether a subject having an inflammatory disease is a candidate for a treatment for the disease, comprising assessing the resolution of inflammation in the subject by determining the presence of a lactoferrin fragment characteristic of resolution having a molecular weight of about 17 kDa in a sample obtained from said subject, wherein the presence of the fragment in said sample indicates that said

subject has inflammation in resolution and the absence of resolution indicates that said subject is a candidate for the treatment, wherein said fragment comprises an amino acid sequence corresponding to positions 172-342 of mammalian lactoferrin, or wherein the fragment characteristic of resolution has a molecular weight of about 17 kDa comprises at least one of SEQ ID NOs: 7-10.

[0102] In another embodiment, said fragment comprises an amino acid sequence corresponding to positions 172-342 of human or bovine lactoferrin; or said fragment has an amino acid sequence as set forth in any one of SEQ ID NOs: 1 and 2.

Lactoferrin fragments

[0103] Also disclosed is a purified lactoferrin fragment of about 17 kDa, which may be isolated from a sample obtained from a subject having resolving inflammation. The fragment is characterized by a molecular weight comparable to that of a lactoferrin fragment obtained from subjects having resolving inflammation but not to that of a lactoferrin fragment obtained from subjects having non-resolving inflammation. The fragment may be isolated and purified from the sample using methods well known in the art (e.g. by gel electrophoresis, gel filtration and affinity chromatography using lactoferrin-specific antibodies). For example, the fragment may be isolated from milk samples or lymph samples, as demonstrated herein. Alternatively, the fragment may be produced by recombinant or synthetic methods known in the art.

[0104] Thus, an isolated lactoferrin fragment characteristic of resolution having a molecular weight of about 17kDa is disclosed. The term "isolated" as used herein with respect to lactoferrin fragments is meant to denote a polypeptide in a substantially pure form corresponding to a naturally occurring lactoferrin fragment which may be found in a mammalian cell, tissue or bodily fluid, and which may be hence isolated from such natural sources, or prepared synthetically or by recombinant methods, and is obtained in isolated form irrespective of the actual way by which said polypeptide is produced. The term "substantially pure" means that the polypeptide is substantially (typically at least 80% or 90%) devoid of other polypeptides, e.g. of other lactoferrin fragments.

[0105] The amino acid sequence of bovine lactoferrin may be represented by SEQ ID NO: 5, accession no. AAA30610, as follows:

MKLFVPALLS	LGALGLCLAA	PRKNVRWCTI	SQPEWFKCRR	WQWRMKKLGA
PSITCVRRAF	ALECIRAI AE	KKADAVTL DG	GMVFEAGRDP	YKLRPVAAEI
YGTKESPQTH	YYAVAVVKKG	SNFQLDQLQG	RKSCHTGLGR	SAGWV I PMGI
LRPYLSWTES	LEPLQGAVAK	FFSASCVPCI	DRQAYPNLCQ	LCKGEGENQC
ACSSREPYFG	YSGAFKCLQD	GAGDVA FVKE	TTVFENLPEK	ADRDQYELLC
LNNSRAPVDA	FKECHLAQVP	SHAVVARSD	GKEDLIWKLL	SKAQEKFGKN
KSRSFQLFGS	PPGQRDLLFK	DSALGFLRIP	SKVDSALYLG	SRYLTTLKLN
RETAEVVKAR	YTRVVWCAVG	PEEQKKCQW	SQQSGQNVTC	ATASTTDDCI
VLVLKGEADA	LNLDGGYIYT	AGKCGLVPVL	AENRKT SKYS	SLDCVLRPTE
GYLAVAVVKK	ANEGLTWNSL	KDKKSCHTAV	DRTAGWNIPM	GLIVNQ TGSC
AFDEFFSQSC	APGRDPKSRL	CALCAGDDQG	LDKCVPSKE	KYYGYTGAFR
CLAEDVGDVA	FVKNDTVWEN	TNGESTADWA	KNLNREDFRL	LCLDGTRKPV
TEAQSCHLAV	APNHAVVSRS	DRAAHVKQVL	LHQQALFGKN	GKNCPDKFCL
FKSETKNLLF	NDNTECLAKL	GGRPTYEEYL	GTEYVTAIAN	LKKCSTSP LL
				EACAFLTR

[0106] The amino acid sequence of human lactoferrin may be represented by SEQ ID NO: 6, accession no. AAA59511, as follows:

	MKLVFLVLLF	LGALGLCLAG	RRRRSVQWCA	VSQPEATKCF	QWQRNMRKVR
	GPPVSCIARD	SPIQCIQAIA	ENRADAVTLD	GGFIYEAGLA	PYKLRPVAAE
5	VYGTERTPRT	HYAVAVVKK	GGSFQLNELQ	GLKSCHTGLR	RTAGWNVPIG
	TLRPFLNWTG	PPEPIEAAVA	RFFSASCVP	ADKGQFPNLC	RLCAGTGENK
	CAFSSQEPYF	SYSGAFKCLR	DGAGDVAFIR	ESTVFEDLSD	EAERDEYELL
10	CPDNTRKPVD	KFKDCHLARV	PSHAVVARSV	NGKEDAIWNL	LRQAQEKFGK
	DKSPKFQLFG	SPSGQKDLLF	KDSAIGFSRV	PPRIDSGLYL	GSGYFTAIQN
	LRKSEEEVAA	RRARVVWCAV	GEQELRKCNQ	WSGLSEGSVT	CSSASTTEDC
15	IALVLKGEAD	AMSLDEGYVY	TAGKCGLPV	LAENYKSQQS	SDPDPCNVDR
	PVEGYLAVAV	VRRSDTSLTW	NSVKGKKSCH	TAVDRTAGWN	IPMGLLFNQ
20	GSCKFDEYFS	QSCAPGSDPR	SNLCALCIGD	EQGENKCVPN	SNERYYYGTG
	AFRCLAENAG	DVAFVKDVT	LQNTDGNNNE	AWAKDLKLAD	FALLCLDGKR
	KPVTEARSCH	LAMAPNHAVV	SRMDKVERLK	QVLLHQQAKF	GRNGSDCPDK
25	FCLFQSETKN	LLFNDNTECL	ARLHGKTTYE	KYLGOPYVAG	ITNLKKCSTS
	PLLEACEFLR K (SEQ ID NO:6).				

30 **[0107]** According to some embodiments, the fragment characteristic of resolution useful as a diagnostic marker in the methods of the invention comprises an amino acid sequence corresponding to positions 172-342 of bovine lactoferrin (e.g. positions 172-342 of SEQ ID NO: 5) or human lactoferrin (e.g. positions 172-342 of SEQ ID NO: 6).

35 **[0108]** According to some embodiments, the fragment having a molecular weight of about 17 kDa useful as a diagnostic marker in the methods of the invention comprises at least one (and preferably 2, 3 or 4) of the following sequences: EPYFGYSGAFKCLQDGAGDVAFFKETTFFENLPEK, SVDGKEDLIWK, VDSALYLGSR and FFSASCVPCIDR (SEQ ID NOs: 7-10, respectively). According to another embodiment, said fragment comprises SEQ ID NOs: 7-10. It is noted that SEQ ID NOs: 7-10 correspond to positions 206-240, 278-288, 333-342 and 171-182 of bovine lactoferrin, respectively. Said fragment can be further characterized in that it does not contain at least one (and preferably 2-8) of the following sequences: WFKCRRWQWRMKKLGAPSITCVRRAF, WCTISQPEWFK, KLGAPSITCVR, RAFALECIR, KA-
40 DAVTLDGGMVFEAGRDYK, LRPVAAEIYGTK, ESPQTHYAVAVVK and KGSNFQLDQLQGR (SEQ ID NOs: 11-18, respectively). Said fragment may not contain SEQ ID NOs: 11-18. Said fragment can be recognized by an antibody directed against an epitope within the sequence LQGAFAFFSASCVPCIDRQAYPNLCQLCKGEGENQCACSSREPY-
FGYSGAFKCLQDGA GDVAFV (SEQ ID NO: 19), e.g. sc-25622 (rabbit anti-mouse lactoferrin polyclonal sera, Santa Cruz Biotechnology, Inc.).

45 **[0109]** According to some embodiments, the fragment having a molecular weight of about 17 kDa useful as a diagnostic marker in the methods of the invention comprises an amino acid sequence corresponding to positions 172-342 of mammalian lactoferrin (e.g. bovine lactoferrin or human lactoferrin). In a particular embodiment, the fragment corresponds to positions 171-342 of bovine lactoferrin (e.g. of SEQ ID NO: 5). In another particular embodiment, the fragment corresponds to positions 172-343 of human lactoferrin (e.g. of SEQ ID NO: 6). Each possibility represents a separate embodiment of the invention.

50 **[0110]** In another particular embodiment the lactoferrin is bovine lactoferrin and said fragment has an amino acid sequence as set forth in SEQ ID NO: 1, as follows:

FFSASCVPCIDRQAYPNLCQLCKGEGENQCACSSREPYFGYSGAFKCLQDGAGDVAFFKETTFF
55 ENLPEKADRDQYELLCLNNSRAPVDAFKECHLAQVPSHAVVARSVDGKEDLIWKLLSKAQEKFG
KNKSRSFQLFGSPPGQRDLLFKDSALGFLRIPSKVDSALYLGSR (SEQ ID NO: 1).

[0111] In another embodiment said fragment has at least 90% amino acid identity to SEQ ID NO: 1. In yet another particular embodiment, said fragment consist essentially of an amino acid sequence as set forth in SEQ ID NO: 1. In yet another particular embodiment, said fragment consist of an amino acid sequence as set forth in SEQ ID NO: 1.

[0112] In another particular embodiment the lactoferrin is human lactoferrin and said fragment has an amino acid sequence as set forth in SEQ ID NO: 2, as follows:

FFSASCVPGADKGQFPNLCRLCAGTGENKCAFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVF
EDLSDEAERDEYELLCPDNTRKPVDFKDKCHLARVP SHAVVARSVNGKEDAIWNLLRQAQEKFG
KDKSPKFQLFGSPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSG (SEQ ID NO: 2).

[0113] In another embodiment said fragment has at least 90% amino acid identity to SEQ ID NO: 2. In yet another particular embodiment, said fragment consist essentially of an amino acid sequence as set forth in SEQ ID NO: 2. In yet another particular embodiment, said fragment consist of an amino acid sequence as set forth in SEQ ID NO: 2.

[0114] In a particular embodiment, the fragment is selected from the group consisting of SEQ ID NOs: 1 and 2.

[0115] Also disclosed is an isolated lactoferrin fragment of about 15 kDa. The fragment is herein identified in samples collected during inflammation, and is thus useful in the diagnostic methods disclosed herein (e.g. for determining the ratio of the fragment of about 17 kDa to about 15 kDa as detailed herein). The fragment comprises at least one (and preferably 2-9) of SEQ ID NOs: 10-18. Said fragment may comprise SEQ ID NOs: 10-18. It is noted that SEQ ID NOs: 10-18 correspond to positions 171-182, 35-60, 27-37, 47-57, 58-66, 72-92, 93-104, 105-118 and 119-131 of bovine lactoferrin, respectively. The fragment may comprise one or more homologs of SEQ ID NOs: 10-18 from other mammalian lactoferrins (e.g. having the corresponding amino acid positions as set forth above). Said fragment can be further characterized in that it does not contain at least one (and preferably 2-3) of SEQ ID NOs: 7-9. Said fragment may not contain

[0116] The fragment may comprise an amino acid sequence corresponding to positions 20-182 of mammalian lactoferrin, or an amino acid sequence corresponding to positions 19-183 of mammalian lactoferrin, or an amino acid sequence corresponding to positions 27-182 of mammalian (e.g. bovine) lactoferrin, or an amino acid sequence corresponding to positions 27-183 of mammalian (e.g. human) lactoferrin. The fragment may correspond to positions 20-182 of bovine lactoferrin or to positions 19-183 of human lactoferrin.

[0117] The isolated lactoferrin fragment may have a molecular weight of about 15kDa, has an amino acid sequence as set forth in any one of SEQ ID NOs: 3 and 4, as follows:

NVRWCTISQPEWFKCRRWQWRMKKLGAPSITCVRRFALECI RAI AEKKADAVTLDGGMVFEAG
RDPYKLRPVAAE IYGTKE SPQTHYYAVAVVKKGSNFQLDQLQGRKSCHTGLGRSAGWV I PMGIL
RPYLSWTESLEPLQGAVAKFFSASCVP C IDR (bovine, SEQ ID NO: 3); and

AGRRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQAI AENRADAVTLDGG
FIYEAGLAPYKLRPVAAEVYGT ERQP RTHYYAVAVVKKGGSFQLNELQGLKSCHTGLRRTAGWN
VPIGTLRPFLNWTGPPEPIEA AVARFFSASCVP GADK (human, SEQ ID NO: 4).

[0118] Said fragment may have at least 90% amino acid identity to SEQ ID NOs: 3 or 4.

[0119] The fragment can be selected from the group consisting of SEQ ID NOs: 3 and 4.

[0120] Polypeptides and peptides may conveniently be produced by recombinant technology. Recombinant methods for designing, expressing and purifying proteins and peptides are known in the art (see, e.g. Sambrook et al., 1989, 1992, 2001, Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York). Nucleic acid molecules may include DNA, RNA, or derivatives of either DNA or RNA. An isolated nucleic acid sequence encoding a polypeptide or peptide can be obtained from its natural source, either as an entire (i.e., complete) gene or a portion thereof. A nucleic acid molecule can also be produced using recombinant DNA technology (e.g., polymerase chain reaction (PCR) amplification, cloning) or chemical synthesis. Nucleic acid sequences include natural nucleic acid sequences and homologs thereof, including, but not limited to, natural allelic variants and modified nucleic acid sequences in which nucleotides have been inserted, deleted, substituted, and/or inverted in such a manner that such modifications do not substantially interfere with the nucleic acid molecule's ability to encode a functional peptide. A polynucleotide or oligonucleotide sequence can be deduced from the genetic code of a protein, however, the degeneracy of the code must be taken into

account, as well as the allowance of exceptions to classical base pairing in the third position of the codon, as given by the so-called "Wobble rules". Polynucleotides that include more or less nucleotides can result in the same or equivalent proteins. Using recombinant production methods, selected host cells, e.g. of a microorganism such as *E. coli* or yeast, are transformed with a hybrid viral or plasmid DNA vector including a specific DNA sequence coding for the polypeptide or polypeptide analog and the polypeptide is synthesized in the host upon transcription and translation of the DNA sequence.

[0121] The sequences may be derived directly from the corresponding sequence of the lactoferrin polypeptide or fragment (such that they may be identical to a portion of a sequence of lactoferrin) or may contain certain derivatizations and substitutions. Thus, the use of salts and functional derivatives of these sequences are contemplated, as long as they retain the respective biologic functions and at least 90% sequence identity, as detailed herein. Accordingly disclosed are polypeptide homologs containing non-natural amino acid derivatives or non-protein side chains. The homologs may be used having a terminal carboxy acid, as a carboxy amide, as a reduced terminal alcohol or as any pharmaceutically acceptable salt, e.g., as metal salt, including sodium, potassium, lithium or calcium salt, or as a salt with an organic base, or as a salt with a mineral acid, including sulfuric acid, hydrochloric acid or phosphoric acid, or with an organic acid e.g., acetic acid or maleic acid. Generally, any pharmaceutically acceptable salt of the peptide may be used, as long as the biological activities of the peptide are maintained.

[0122] Also disclosed are derivatives containing non-natural amino acid derivatives or non-protein side chains. The polypeptides and derivatives may be used having a terminal carboxy acid, as a carboxy amide, as a reduced terminal alcohol or as any pharmaceutically acceptable salt, e.g., as metal salt, including sodium, potassium, lithium or calcium salt, or as a salt with an organic base, or as a salt with a mineral acid, including sulfuric acid, hydrochloric acid or phosphoric acid, or with an organic acid e.g., acetic acid or maleic acid. Generally, any pharmaceutically acceptable salt of the polypeptides and peptides utilized in methods of the invention may be used, as long as the biological activities of the polypeptide are maintained.

[0123] The amino acid residues described herein are preferred to be in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the peptide substantially retains the desired functional property.

[0124] Chemical derivatives may have one or more residues chemically derivatized by reaction of side chains or functional groups. Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those peptides, which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acid residues. For example: 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine.

[0125] In addition, a derivative can differ from the natural sequence of the polypeptides or peptides by chemical modifications including, but are not limited to, terminal-NH₂ acylation, acetylation, or thioglycolic acid amidation, and by terminal-carboxyamidation, e.g., with ammonia, methylamine, and the like.

[0126] The following examples are presented to provide a more complete understanding of the invention. The specific techniques, conditions, materials, proportions and reported data set forth to illustrate the principles of the invention are exemplary and should not be construed as limiting the scope of the invention.

EXAMPLES

Experimental procedures

Peritonitis induction and leukocyte isolation

[0127] Neutrophils and macrophages were isolated from peritoneal exudates as follows: Male C57BL/6 mice (6-8 wk; protocol approved by the Committee of Ethics, University of Haifa) were injected I.P. with zymosan A (1 mg in 1 ml). After 24 hr (for neutrophils) or 66 hr (for macrophages) mice were euthanized with CO₂ and peritoneal exudates were collected by lavaging with 5 ml of sterile saline. Exudate cells were stained on ice for 20 min with PE-conjugated rat anti-mouse Ly-6G (clone RBC-8C5) or PE-conjugated rat anti-mouse F4/80 (clone CI:A3-1), and washed twice with 1%BSA in PBS. Then, neutrophils or macrophages were isolated using magnetic bead-conjugated anti-PE antibodies and a separation kit (Stem cell) according to the manufacturer's instructions. Macrophages were cultured 2X10⁶/well in 6 well plates.

Apoptotic cells

[0128] Polymorphonuclear leukocyte (PMN) were allowed to undergo apoptosis by culture ex vivo in culture media. Jurkat cells were induced to undergo apoptosis by addition of staurosporine (1 μ M) for 4 hrs.

Apoptotic cell co-cultures

[0129] Macrophages were incubated with senescent neutrophils or apoptotic Jurkat cells (1:5 ratio) for 24 hrs. Senescent neutrophils were used as controls. Following co culture unbound cells were washed with PBS and attached macrophages were recovered and lysed by RIPA buffer.

Milk preparation

[0130] Milk samples were obtained from dairy cows undergoing resolving or non-resolving *E-coli* induced mastitis, or healthy cows. In order to separate the cellular and fat fraction from the aqueous fraction, samples were centrifuge at 1200 rpm for 5 minutes (cellular fraction), and the supernatants were transferred to 4° to solidify the fat fraction. After cooling overnight, the fat fraction was mechanically peeled from samples and the protein content in the soluble fraction was determined. Then, milk samples were added with sample buffer and run by SDS-PAGE. The cellular fraction was treated as the macrophage preparations described above.

Western blot analysis

[0131] Protein extracts were boiled prior to loading for 5 minutes in sample buffer, containing (for sample buffer x2) 150mM Tris pH 6.8, 20% glycerol, 4% SDS, 5% β -mercaptoethanol, and 15ug/ml bromophenol blue. Equal amount of protein extracts from murine macrophages, bovine milk cells or bovine milk were run using 10% SDS-PAGE (5 μ g/lane), transferred (1h, 15V) to a nitrocellulose membranes (Bio-rad) blocked for 1h with 5%BSA in TBST and immuno-blotted over night at 40°C with Rabbit anti-mouse/human lactoferrin (sc-25622, Santa Cruz Biotechnology, Inc.). Then, the membranes were washed 3 times with TBST, and incubated with the appropriate HRP-conjugated secondary antibody (1:10,000, 1hr, room temperature, Jackson ImmunoResearch). The blots were washed and developed using EZ-ECL (Biological Industries) chemiluminescence kit and analyzed using the LAS-4000 luminescent image analyzer (FUJIFILM) and the TotalLab TL-100 software (Nonlinear Dynamics).

Interstitial fluid preparation from lymphatic organs.

[0132] Inguinal and spleen lymph nodes were harvested from mice 24 or 66 hrs post peritonitis initiation (n=9). The organs were mechanically dissociated and strained through a 100 μ m nylon mesh (Beckton-Dickinson) to produce a single cell suspension, followed by separation of cells from interstitial fluids by centrifugation (1,200 RPM X 5 minutes). Then, red blood cells (RBC) were lysed using lysis buffer (biological industry) and interstitial fluids were saved at -20°C for further analysis.

[0133] Interstitial fluids were added with sample buffer (1:1), boiled as indicated above, and equal protein amounts were run by SDS-PAGE (7.5% or 10%, acrylamide with 1-3% SDS at 80V for 30 minutes for upper gel and 120V for 90 minutes for lower gel) and transferred to a PVDF membrane. The membrane was blocked with 5% BSA and probed with rabbit antihuman/mouse Lactoferrin polyclonal IgG (sc-25622, Santa Cruz Biotechnology, Inc., 1:200 dilution), followed by a matching secondary antibody conjugated with horseradish peroxidase (HRP, 1:20,000 dilution). Membranes were developed with EZ-ECL detection kit (Biological Industries, Beit Haemek) and analyzed using Luminescent Image Analyzer LAS-4000 (Fujifilm Corporation) and "Image Reader LAS-4000" software (Fujifilm Corporation). Densitometry analysis were performed using TotalLab TL100 (nonlinear dynamics) image analysis software.

Example 1: Lactoferrin is processed by macrophages incubated with apoptotic neutrophils

[0134] During the resolution of inflammation, macrophages uptake apoptotic polymorphonuclear cells (PMN) and migrate to the lymphatics. The presence of lactoferrin was examined in macrophages following engulfment of apoptotic PMN. To this end, peritoneal mouse macrophages were recovered 66 hrs after zymosan A injection. Then, the macrophages were incubated with apoptotic Jurkat cells (control, lane 2) or apoptotic neutrophils (lane 4). Apoptotic neutrophils (lane 3) or macrophages not incubated with apoptotic cells (lane 1) were used as controls as indicated. After incubation, cell lysates were prepared and run by SDS-PAGE and Western blot for lactoferrin.

[0135] As depicted in Fig. 1, in murine macrophages, a lactoferrin fragment (50 kDa), rather than the full length protein, was detected. Without wishing to be bound by any theory or mechanism, the lactoferrin fragment was most likely acquired

from apoptotic PMN previously taken up by these macrophages. Senescent PMN contain full length lactoferrin and when engulfed by macrophages transfer considerable amounts of it to the macrophages. Lactoferrin is not transcribed de novo by macrophages and processed following the encounter of apoptotic cells as evident from the incubation of macrophages with apoptotic Jurkat cells (lane 2 in FIG. 1). The reduction in the 50 kDa fragment level following macrophage incubation with apoptotic cells suggests that this fragment is released following the uptake of apoptotic neutrophils.

[0136] These results indicate that lactoferrin present in neutrophil secondary granules is retained in apoptotic neutrophils, acquired by macrophages that clear these neutrophils, and processed by proteolysis to smaller fragments during the resolution of inflammation.

Example 2: Lactoferrin fragments present during inflammation and resolution in bovine mastitis

[0137] To determine whether lactoferrin fragments can be found in body fluids during the resolution of inflammation, milk samples from dairy cows that developed mastitis following infection with *E. coli* (Fig. 2A) were analyzed. Cows that did not clear the infection or healthy cows were used as controls (Fig. 2B).

[0138] The results indicate changes in the levels of several lactoferrin fragments during the inflammation-resolution switch. At days 1-3, a reduction in the amounts of the 75 and 55 kDa fragments was observed, wherein these fragments reappeared on days 4-7. The levels of the 23 and 15 kDa fragments reduced continuously on days 1-7, and the amounts of the 17 kDa fragment increased continuously between days 2-7. Most lactoferrin fragments were found in the cellular fraction of the milk and followed a similar but forward-pulled kinetics to the levels in the soluble fraction.

[0139] In non-resolving mastitis, a continuous increase in the levels of the 50 kDa fragment was observed, with a very late appearance of the 23 kDa fragment, and very low levels of the smaller fragments. In milk obtained from healthy cows, lactoferrin was barely detectable (at fragment sizes of 50, 30, and 25 kDa).

[0140] Thus the results indicate that the levels of lactoferrin fragments may be used to monitor the progress and fate of inflammation, and that the ratio between lactoferrin fragments of 23 and 17 kDa can be used as a diagnostic marker for transition from inflammation to resolution.

Example 3: Lactoferrin fragments are released to the interstitial space in spleen and inguinal lymph nodes during inflammation and resolution in murine peritonitis

[0141] Since macrophages migrate to lymphoid organs during the resolution of inflammation, the inventors sought to determine whether lactoferrin fragments can be found in soluble forms at lymphoid organs, and whether their amounts change upon the shift from inflammation to resolution. To do so spleen and inguinal lymph nodes were harvested at two time periods (24 and 66 hrs) after peritonitis initiation and their interstitial fluids were assessed for Lactoferrin fragments content.

[0142] The results indicate that different amounts of several Lactoferrin cleavage products can be detected at 24 and 66 hrs post peritonitis initiation at the spleen and inguinal lymph nodes (LN; Figure 3). The cleaved products of lactoferrin are similar in their molecular weight in either organ, and can be roughly defined as six distinguishable fragments of 50, 37, 23, 21, 17 and 15 kDa (as evaluated by SDS-PAGE), in addition to the full length 78 kDa protein. Significant differences were detected between spleen and inguinal LN during inflammation (24 hrs) and its resolution (66 hrs). There is a significant reduction in the amount of the 23 and 15 kDa fragments (5 fold and 4 fold, respectively) in the spleen, whereas an increase in the amount of the 21 and 17 kDa fragments (11 fold and 8 fold, respectively) can be detected (Figure 3, A-B). In the inguinal LN however, a significant reduction in the amount of the 78, 23 and 15 kDa fragments (5 fold, 3 fold and 16 fold, respectively) could be noticed and an increase in the amount of the 17 kDa fragment (5 fold) is observed (Figure 3, C-D). Thus, the amounts of different Lactoferrin fragments in the interstitial fluids from the spleen and inguinal LN change as inflammation resolves.

[0143] It can further be observed that the 17kDa fragment can be identified as a common marker for resolving inflammation, since the amount of this fragment consistently increased during the transit from inflammation to resolution in both spleen and LN.

Example 4: Isolation of bovine Lactoferrin and its derived fragments from mastitis-inflicted cows

[0144] Bovine lactoferrin was purified from mastitis-inflicted milk samples collected at day 3 or day 5 from the onset of infection. Milk samples were defatted by centrifugation at 2000 g for 30 min at 4°C, followed by mechanically scarping of the upper fat layer. The pH of the skim milk was adjusted to 4.6 with 5 N HCl and then centrifuged at 10,000 g for 1 hr to remove the casein precipitate. The whey was passed through a 0.45 mm filter to completely remove the casein precipitate and its pH was readjusted to 6.0 with 1N NaOH. The immunoglobulin in the whey was removed by ammonium sulfate precipitation (48%) for 30 min rotation in room temperature followed by 10,000 g centrifugation for 30 min. The solution in the whey was then replaced with 0.005 M sodium phosphate buffer (pH 6.0) using a 12-14 kDa cutoff membrane

dialysis bag. Then, the samples were loaded onto a heparin affinity column and eluted by 3 step elution with 0.005 M sodium phosphate buffer (pH 6.0) containing 0.1, 0.3 or 0.5 M NaCl. The flowthrough was collected and lactoferrin-derived products were assessed by SDS-PAGE and Western blotting.

[0145] The results are presented in Fig. 4, showing molecular weight assessment of the resulting isolated fragments by SDS-PAGE and Western blotting using secondary antibody only (FIG. 4A) or anti-lactoferrin sera and secondary antibody (FIG. 4B). As can be seen in FIG. 4B a fragment of about 15 kDa may be detected at day 3, and decreases in amount by day 5. A fragment of about 17 kDa appears at day 5.

[0146] The fragments evaluated as being about 15 and 17 kDa following gel electrophoresis (day 5, 0.5M NaCl) were isolated from the gel, and subjected to proteolytic cleavage by Trypsin and Liquid chromatography-tandem mass spectrometry (LC-MS/MS) on LTQ-orbitrap mass spectrometer. Proteomic sequence analysis was performed by discoverer software version 1.3 against bovine part of the nr database and against decoy databases to determine false discovery rate (FDR). High identification confidence refers to 0.01 FDR.

SEQUENCE LISTING

[0147]

<110> CARMEL-HAIFA UNIVERSITY ECONOMIC CORP ARIEL , Amiram LUTATI , Aviv

<120> LACTOFERRIN FRAGMENTS AND USE THEREOF

<130> CRML/002 PCT

<160> 19

<170> PatentIn version 3.5

<210> 1

<211> 172

<212> PRT

<213> Bos taurus

<400> 1

EP 2 734 543 B1

	Phe	Phe	Ser	Ala	Ser	Cys	Val	Pro	Cys	Ile	Asp	Arg	Gln	Ala	Tyr	Pro	
	1				5					10					15		
5	Asn	Leu	Cys	Gln	Leu	Cys	Lys	Gly	Glu	Gly	Glu	Asn	Gln	Cys	Ala	Cys	
				20					25					30			
10	Ser	Ser	Arg	Glu	Pro	Tyr	Phe	Gly	Tyr	Ser	Gly	Ala	Phe	Lys	Cys	Leu	
			35					40					45				
15	Gln	Asp	Gly	Ala	Gly	Asp	Val	Ala	Phe	Val	Lys	Glu	Thr	Thr	Val	Phe	
	50						55					60					
20	Glu	Asn	Leu	Pro	Glu	Lys	Ala	Asp	Arg	Asp	Gln	Tyr	Glu	Leu	Leu	Cys	
	65					70					75					80	
25	Leu	Asn	Asn	Ser	Arg	Ala	Pro	Val	Asp	Ala	Phe	Lys	Glu	Cys	His	Leu	
					85					90					95		
30	Ala	Gln	Val	Pro	Ser	His	Ala	Val	Val	Ala	Arg	Ser	Val	Asp	Gly	Lys	
				100					105					110			
35	Glu	Asp	Leu	Ile	Trp	Lys	Leu	Leu	Ser	Lys	Ala	Gln	Glu	Lys	Phe	Gly	
			115				120						125				
40	Lys	Asn	Lys	Ser	Arg	Ser	Phe	Gln	Leu	Phe	Gly	Ser	Pro	Pro	Gly	Gln	
		130					135					140					
45	Arg	Asp	Leu	Leu	Phe	Lys	Asp	Ser	Ala	Leu	Gly	Phe	Leu	Arg	Ile	Pro	
	145					150					155					160	
50	Ser	Lys	Val	Asp	Ser	Ala	Leu	Tyr	Leu	Gly	Ser	Arg					
					165					170							

<210> 2

<211> 172

<212> PRT

<213> Homo sapiens

<400> 2

EP 2 734 543 B1

	Phe	Phe	Ser	Ala	Ser	Cys	Val	Pro	Gly	Ala	Asp	Lys	Gly	Gln	Phe	Pro
	1				5					10					15	
5	Asn	Leu	Cys	Arg	Leu	Cys	Ala	Gly	Thr	Gly	Glu	Asn	Lys	Cys	Ala	Phe
				20					25					30		
10	Ser	Ser	Gln	Glu	Pro	Tyr	Phe	Ser	Tyr	Ser	Gly	Ala	Phe	Lys	Cys	Leu
			35					40					45			
15	Arg	Asp	Gly	Ala	Gly	Asp	Val	Ala	Phe	Ile	Arg	Glu	Ser	Thr	Val	Phe
	50						55					60				
20	Glu	Asp	Leu	Ser	Asp	Glu	Ala	Glu	Arg	Asp	Glu	Tyr	Glu	Leu	Leu	Cys
	65					70					75					80
25	Pro	Asp	Asn	Thr	Arg	Lys	Pro	Val	Asp	Lys	Phe	Lys	Asp	Cys	His	Leu
					85					90					95	
30	Ala	Arg	Val	Pro	Ser	His	Ala	Val	Val	Ala	Arg	Ser	Val	Asn	Gly	Lys
				100					105					110		
35	Glu	Asp	Ala	Ile	Trp	Asn	Leu	Leu	Arg	Gln	Ala	Gln	Glu	Lys	Phe	Gly
			115					120					125			
40	Lys	Asp	Lys	Ser	Pro	Lys	Phe	Gln	Leu	Phe	Gly	Ser	Pro	Ser	Gly	Gln
		130					135					140				
45	Lys	Asp	Leu	Leu	Phe	Lys	Asp	Ser	Ala	Ile	Gly	Phe	Ser	Arg	Val	Pro
	145					150					155					160
50	Pro	Arg	Ile	Asp	Ser	Gly	Leu	Tyr	Leu	Gly	Ser	Gly				
					165					170						
	<210> 3															
	<211> 163															
	<212> PRT															
	<213> Bos taurus															
	<400> 3															
55	Ala	Pro	Arg	Lys	Asn	Val	Arg	Trp	Cys	Thr	Ile	Ser	Gln	Pro	Glu	Trp
	1				5					10					15	

EP 2 734 543 B1

	Phe	Lys	Cys	Arg	Arg	Trp	Gln	Trp	Arg	Met	Lys	Lys	Leu	Gly	Ala	Pro	
				20					25					30			
5	Ser	Ile	Thr	Cys	Val	Arg	Arg	Ala	Phe	Ala	Leu	Glu	Cys	Ile	Arg	Ala	
			35					40					45				
10	Ile	Ala	Glu	Lys	Lys	Ala	Asp	Ala	Val	Thr	Leu	Asp	Gly	Gly	Met	Val	
	50						55					60					
15	Phe	Glu	Ala	Gly	Arg	Asp	Pro	Tyr	Lys	Leu	Arg	Pro	Val	Ala	Ala	Glu	
	65					70					75					80	
20	Ile	Tyr	Gly	Thr	Lys	Glu	Ser	Pro	Gln	Thr	His	Tyr	Tyr	Ala	Val	Ala	
					85					90					95		
25	Val	Val	Lys	Lys	Gly	Ser	Asn	Phe	Gln	Leu	Asp	Gln	Leu	Gln	Gly	Arg	
				100					105					110			
30	Lys	Ser	Cys	His	Thr	Gly	Leu	Gly	Arg	Ser	Ala	Gly	Trp	Val	Ile	Pro	
			115					120					125				
35	Met	Gly	Ile	Leu	Arg	Pro	Tyr	Leu	Ser	Trp	Thr	Glu	Ser	Leu	Glu	Pro	
	130						135					140					
40	Leu	Gln	Gly	Ala	Val	Ala	Lys	Phe	Phe	Ser	Ala	Ser	Cys	Val	Pro	Cys	
	145					150					155					160	
45	Ile	Asp	Arg														
	<210> 4																
	<211> 165																
	<212> PRT																
	<213> Homo sapiens																
	<400> 4																
50	Ala	Gly	Arg	Arg	Arg	Arg	Ser	Val	Gln	Trp	Cys	Ala	Val	Ser	Gln	Pro	
	1				5					10					15		
55	Glu	Ala	Thr	Lys	Cys	Phe	Gln	Trp	Gln	Arg	Asn	Met	Arg	Lys	Val	Arg	
				20					25					30			
60	Gly	Pro	Pro	Val	Ser	Cys	Ile	Lys	Arg	Asp	Ser	Pro	Ile	Gln	Cys	Ile	
			35					40					45				
65	Gln	Ala	Ile	Ala	Glu	Asn	Arg	Ala	Asp	Ala	Val	Thr	Leu	Asp	Gly	Gly	
	50						55					60					

EP 2 734 543 B1

	Phe	Ile	Tyr	Glu	Ala	Gly	Leu	Ala	Pro	Tyr	Lys	Leu	Arg	Pro	Val	Ala	
	65					70					75					80	
5	Ala	Glu	Val	Tyr	Gly	Thr	Glu	Arg	Gln	Pro	Arg	Thr	His	Tyr	Tyr	Ala	
					85					90					95		
10	Val	Ala	Val	Val	Lys	Lys	Gly	Gly	Ser	Phe	Gln	Leu	Asn	Glu	Leu	Gln	
				100					105					110			
15	Gly	Leu	Lys	Ser	Cys	His	Thr	Gly	Leu	Arg	Arg	Thr	Ala	Gly	Trp	Asn	
			115					120					125				
20	Val	Pro	Ile	Gly	Thr	Leu	Arg	Pro	Phe	Leu	Asn	Trp	Thr	Gly	Pro	Pro	
	130						135					140					
25	Glu	Pro	Ile	Glu	Ala	Ala	Val	Ala	Arg	Phe	Phe	Ser	Ala	Ser	Cys	Val	
	145					150					155					160	
30	Pro	Gly	Ala	Asp	Lys												
					165												
	<210> 5																
	<211> 708																
	<212> PRT																
	<213> Bos taurus																
	<400> 5																
35	Met	Lys	Leu	Phe	Val	Pro	Ala	Leu	Leu	Ser	Leu	Gly	Ala	Leu	Gly	Leu	
	1				5					10					15		
40	Cys	Leu	Ala	Ala	Pro	Arg	Lys	Asn	Val	Arg	Trp	Cys	Thr	Ile	Ser	Gln	
			20					25						30			
45	Pro	Glu	Trp	Phe	Lys	Cys	Arg	Arg	Trp	Gln	Trp	Arg	Met	Lys	Lys	Leu	
		35					40						45				
50	Gly	Ala	Pro	Ser	Ile	Thr	Cys	Val	Arg	Arg	Ala	Phe	Ala	Leu	Glu	Cys	
	50						55					60					
55	Ile	Arg	Ala	Ile	Ala	Glu	Lys	Lys	Ala	Asp	Ala	Val	Thr	Leu	Asp	Gly	
	65					70				75						80	
	Gly	Met	Val	Phe	Glu	Ala	Gly	Arg	Asp	Pro	Tyr	Lys	Leu	Arg	Pro	Val	
					85				90						95		
	Ala	Ala	Glu	Ile	Tyr	Gly	Thr	Lys	Glu	Ser	Pro	Gln	Thr	His	Tyr	Tyr	
				100					105					110			

EP 2 734 543 B1

	Ala	Val	Ala	Val	Val	Lys	Lys	Gly	Ser	Asn	Phe	Gln	Leu	Asp	Gln	Leu	
			115					120					125				
5	Gln	Gly	Arg	Lys	Ser	Cys	His	Thr	Gly	Leu	Gly	Arg	Ser	Ala	Gly	Trp	
		130					135					140					
	Val	Ile	Pro	Met	Gly	Ile	Leu	Arg	Pro	Tyr	Leu	Ser	Trp	Thr	Glu	Ser	
10		145				150					155					160	
	Leu	Glu	Pro	Leu	Gln	Gly	Ala	Val	Ala	Lys	Phe	Phe	Ser	Ala	Ser	Cys	
					165					170					175		
15	Val	Pro	Cys	Ile	Asp	Arg	Gln	Ala	Tyr	Pro	Asn	Leu	Cys	Gln	Leu	Cys	
				180					185					190			
	Lys	Gly	Glu	Gly	Glu	Asn	Gln	Cys	Ala	Cys	Ser	Ser	Arg	Glu	Pro	Tyr	
20			195					200					205				
	Phe	Gly	Tyr	Ser	Gly	Ala	Phe	Lys	Cys	Leu	Gln	Asp	Gly	Ala	Gly	Asp	
25		210					215					220					
	Val	Ala	Phe	Val	Lys	Glu	Thr	Thr	Val	Phe	Glu	Asn	Leu	Pro	Glu	Lys	
		225				230					235					240	
30	Ala	Asp	Arg	Asp	Gln	Tyr	Glu	Leu	Leu	Cys	Leu	Asn	Asn	Ser	Arg	Ala	
					245					250					255		
	Pro	Val	Asp	Ala	Phe	Lys	Glu	Cys	His	Leu	Ala	Gln	Val	Pro	Ser	His	
35				260					265					270			
	Ala	Val	Val	Ala	Arg	Ser	Val	Asp	Gly	Lys	Glu	Asp	Leu	Ile	Trp	Lys	
			275					280					285				
40	Leu	Leu	Ser	Lys	Ala	Gln	Glu	Lys	Phe	Gly	Lys	Asn	Lys	Ser	Arg	Ser	
		290					295					300					
	Phe	Gln	Leu	Phe	Gly	Ser	Pro	Pro	Gly	Gln	Arg	Asp	Leu	Leu	Phe	Lys	
45		305				310					315					320	
	Asp	Ser	Ala	Leu	Gly	Phe	Leu	Arg	Ile	Pro	Ser	Lys	Val	Asp	Ser	Ala	
50					325					330				335			
	Leu	Tyr	Leu	Gly	Ser	Arg	Tyr	Leu	Thr	Thr	Leu	Lys	Asn	Leu	Arg	Glu	
				340					345					350			
55	Thr	Ala	Glu	Glu	Val	Lys	Ala	Arg	Tyr	Thr	Arg	Val	Val	Trp	Cys	Ala	
			355					360					365				

EP 2 734 543 B1

	Val	Gly	Pro	Glu	Glu	Gln	Lys	Lys	Cys	Gln	Gln	Trp	Ser	Gln	Gln	Ser
	370						375					380				
5	Gly	Gln	Asn	Val	Thr	Cys	Ala	Thr	Ala	Ser	Thr	Thr	Asp	Asp	Cys	Ile
	385					390					395					400
10	Val	Leu	Val	Leu	Lys	Gly	Glu	Ala	Asp	Ala	Leu	Asn	Leu	Asp	Gly	Gly
					405					410					415	
15	Tyr	Ile	Tyr	Thr	Ala	Gly	Lys	Cys	Gly	Leu	Val	Pro	Val	Leu	Ala	Glu
				420					425					430		
20	Asn	Arg	Lys	Thr	Ser	Lys	Tyr	Ser	Ser	Leu	Asp	Cys	Val	Leu	Arg	Pro
			435					440					445			
25	Thr	Glu	Gly	Tyr	Leu	Ala	Val	Ala	Val	Val	Lys	Lys	Ala	Asn	Glu	Gly
	450						455					460				
30	Leu	Thr	Trp	Asn	Ser	Leu	Lys	Asp	Lys	Lys	Ser	Cys	His	Thr	Ala	Val
	465					470					475					480
35	Asp	Arg	Thr	Ala	Gly	Trp	Asn	Ile	Pro	Met	Gly	Leu	Ile	Val	Asn	Gln
					485					490					495	
40	Thr	Gly	Ser	Cys	Ala	Phe	Asp	Glu	Phe	Phe	Ser	Gln	Ser	Cys	Ala	Pro
				500					505					510		
45	Gly	Arg	Asp	Pro	Lys	Ser	Arg	Leu	Cys	Ala	Leu	Cys	Ala	Gly	Asp	Asp
			515					520					525			
50	Gln	Gly	Leu	Asp	Lys	Cys	Val	Pro	Asn	Ser	Lys	Glu	Lys	Tyr	Tyr	Gly
	530						535					540				
55	Tyr	Thr	Gly	Ala	Phe	Arg	Cys	Leu	Ala	Glu	Asp	Val	Gly	Asp	Val	Ala
	545					550					555					560
60	Phe	Val	Lys	Asn	Asp	Thr	Val	Trp	Glu	Asn	Thr	Asn	Gly	Glu	Ser	Thr
				565						570					575	
65	Ala	Asp	Trp	Ala	Lys	Asn	Leu	Asn	Arg	Glu	Asp	Phe	Arg	Leu	Leu	Cys
				580					585					590		
70	Leu	Asp	Gly	Thr	Arg	Lys	Pro	Val	Thr	Glu	Ala	Gln	Ser	Cys	His	Leu
			595					600					605			
75	Ala	Val	Ala	Pro	Asn	His	Ala	Val	Val	Ser	Arg	Ser	Asp	Arg	Ala	Ala

EP 2 734 543 B1

610

615

620

5

His Val Lys Gln Val Leu Leu His Gln Gln Ala Leu Phe Gly Lys Asn
625 630 635 640

10

Gly Lys Asn Cys Pro Asp Lys Phe Cys Leu Phe Lys Ser Glu Thr Lys
645 650 655

15

Asn Leu Leu Phe Asn Asp Asn Thr Glu Cys Leu Ala Lys Leu Gly Gly
660 665 670

20

Arg Pro Thr Tyr Glu Glu Tyr Leu Gly Thr Glu Tyr Val Thr Ala Ile
675 680 685

Ala Asn Leu Lys Lys Cys Ser Thr Ser Pro Leu Leu Glu Ala Cys Ala
690 695 700

Phe Leu Thr Arg
705

25

<210> 6
<211> 711
<212> PRT
<213> Homo sapiens

30

<400> 6

35

40

45

50

55

EP 2 734 543 B1

Met	Lys	Leu	Val	Phe	Leu	Val	Leu	Leu	Phe	Leu	Gly	Ala	Leu	Gly	Leu
1				5					10					15	
Cys	Leu	Ala	Gly	Arg	Arg	Arg	Arg	Ser	Val	Gln	Trp	Cys	Ala	Val	Ser
			20					25					30		
Gln	Pro	Glu	Ala	Thr	Lys	Cys	Phe	Gln	Trp	Gln	Arg	Asn	Met	Arg	Lys
		35					40					45			
Val	Arg	Gly	Pro	Pro	Val	Ser	Cys	Ile	Lys	Arg	Asp	Ser	Pro	Ile	Gln
	50					55					60				
Cys	Ile	Gln	Ala	Ile	Ala	Glu	Asn	Arg	Ala	Asp	Ala	Val	Thr	Leu	Asp
65					70					75					80
Gly	Gly	Phe	Ile	Tyr	Glu	Ala	Gly	Leu	Ala	Pro	Tyr	Lys	Leu	Arg	Pro
				85					90					95	
Val	Ala	Ala	Glu	Val	Tyr	Gly	Thr	Glu	Arg	Gln	Pro	Arg	Thr	His	Tyr
			100					105					110		
Tyr	Ala	Val	Ala	Val	Val	Lys	Lys	Gly	Gly	Ser	Phe	Gln	Leu	Asn	Glu

EP 2 734 543 B1

	115					120					125					
5	Leu	Gln	Gly	Leu	Lys	Ser	Cys	His	Thr	Gly	Leu	Arg	Arg	Thr	Ala	Gly
	130						135					140				
10	Trp	Asn	Val	Pro	Ile	Gly	Thr	Leu	Arg	Pro	Phe	Leu	Asn	Trp	Thr	Gly
	145					150					155					160
15	Pro	Pro	Glu	Pro	Ile	Glu	Ala	Ala	Val	Ala	Arg	Phe	Phe	Ser	Ala	Ser
					165					170					175	
20	Cys	Val	Pro	Gly	Ala	Asp	Lys	Gly	Gln	Phe	Pro	Asn	Leu	Cys	Arg	Leu
				180					185					190		
25	Cys	Ala	Gly	Thr	Gly	Glu	Asn	Lys	Cys	Ala	Phe	Ser	Ser	Gln	Glu	Pro
			195					200					205			
30	Tyr	Phe	Ser	Tyr	Ser	Gly	Ala	Phe	Lys	Cys	Leu	Arg	Asp	Gly	Ala	Gly
	210						215					220				
35	Asp	Val	Ala	Phe	Ile	Arg	Glu	Ser	Thr	Val	Phe	Glu	Asp	Leu	Ser	Asp
	225					230					235					240
40	Glu	Ala	Glu	Arg	Asp	Glu	Tyr	Glu	Leu	Leu	Cys	Pro	Asp	Asn	Thr	Arg
					245					250					255	
45	Lys	Pro	Val	Asp	Lys	Phe	Lys	Asp	Cys	His	Leu	Ala	Arg	Val	Pro	Ser
				260					265					270		
50	His	Ala	Val	Val	Ala	Arg	Ser	Val	Asn	Gly	Lys	Glu	Asp	Ala	Ile	Trp
			275					280					285			
55	Asn	Leu	Leu	Arg	Gln	Ala	Gln	Glu	Lys	Phe	Gly	Lys	Asp	Lys	Ser	Pro
	290						295					300				
60	Lys	Phe	Gln	Leu	Phe	Gly	Ser	Pro	Ser	Gly	Gln	Lys	Asp	Leu	Leu	Phe
	305					310					315					320
65	Lys	Asp	Ser	Ala	Ile	Gly	Phe	Ser	Arg	Val	Pro	Pro	Arg	Ile	Asp	Ser
					325					330					335	
70	Gly	Leu	Tyr	Leu	Gly	Ser	Gly	Tyr	Phe	Thr	Ala	Ile	Gln	Asn	Leu	Arg
				340					345					350		
75	Lys	Ser	Glu	Glu	Glu	Val	Ala	Ala	Arg	Arg	Ala	Arg	Val	Val	Trp	Cys
			355					360					365			

EP 2 734 543 B1

	Ala	Val	Gly	Glu	Gln	Glu	Leu	Arg	Lys	Cys	Asn	Gln	Trp	Ser	Gly	Leu	
	370						375					380					
5	Ser	Glu	Gly	Ser	Val	Thr	Cys	Ser	Ser	Ala	Ser	Thr	Thr	Glu	Asp	Cys	
	385					390					395					400	
10	Ile	Ala	Leu	Val	Leu	Lys	Gly	Glu	Ala	Asp	Ala	Met	Ser	Leu	Asp	Glu	
					405					410					415		
	Gly	Tyr	Val	Tyr	Thr	Ala	Gly	Lys	Cys	Gly	Leu	Val	Pro	Val	Leu	Ala	
				420					425					430			
15	Glu	Asn	Tyr	Lys	Ser	Gln	Gln	Ser	Ser	Asp	Pro	Asp	Pro	Asn	Cys	Val	
			435					440					445				
20	Asp	Arg	Pro	Val	Glu	Gly	Tyr	Leu	Ala	Val	Ala	Val	Val	Arg	Arg	Ser	
	450						455					460					
25	Asp	Thr	Ser	Leu	Thr	Trp	Asn	Ser	Val	Lys	Gly	Lys	Lys	Ser	Cys	His	
	465					470					475					480	
	Thr	Ala	Val	Asp	Arg	Thr	Ala	Gly	Trp	Asn	Ile	Pro	Met	Gly	Leu	Leu	
					485					490					495		
30	Phe	Asn	Gln	Thr	Gly	Ser	Cys	Lys	Phe	Asp	Glu	Tyr	Phe	Ser	Gln	Ser	
				500					505					510			
35	Cys	Ala	Pro	Gly	Ser	Asp	Pro	Arg	Ser	Asn	Leu	Cys	Ala	Leu	Cys	Ile	
			515					520					525				
40	Gly	Asp	Glu	Gln	Gly	Glu	Asn	Lys	Cys	Val	Pro	Asn	Ser	Asn	Glu	Arg	
	530						535					540					
	Tyr	Tyr	Gly	Tyr	Thr	Gly	Ala	Phe	Arg	Cys	Leu	Ala	Glu	Asn	Ala	Gly	
	545					550					555					560	
45	Asp	Val	Ala	Phe	Val	Lys	Asp	Val	Thr	Val	Leu	Gln	Asn	Thr	Asp	Gly	
					565					570					575		
50	Asn	Asn	Asn	Glu	Ala	Trp	Ala	Lys	Asp	Leu	Lys	Leu	Ala	Asp	Phe	Ala	
				580					585					590			
	Leu	Leu	Cys	Leu	Asp	Gly	Lys	Arg	Lys	Pro	Val	Thr	Glu	Ala	Arg	Ser	
			595					600					605				
55	Cys	His	Leu	Ala	Met	Ala	Pro	Asn	His	Ala	Val	Val	Ser	Arg	Met	Asp	
	610						615					620					

EP 2 734 543 B1

	Lys	Val	Glu	Arg	Leu	Lys	Gln	Val	Leu	Leu	His	Gln	Gln	Ala	Lys	Phe	
	625					630					635					640	
5	Gly	Arg	Asn	Gly	Ser	Asp	Cys	Pro	Asp	Lys	Phe	Cys	Leu	Phe	Gln	Ser	
					645					650					655		
10	Glu	Thr	Lys	Asn	Leu	Leu	Phe	Asn	Asp	Asn	Thr	Glu	Cys	Leu	Ala	Arg	
				660					665						670		
15	Leu	His	Gly	Lys	Thr	Thr	Tyr	Glu	Lys	Tyr	Leu	Gly	Pro	Gln	Tyr	Val	
			675					680					685				
20	Ala	Gly	Ile	Thr	Asn	Leu	Lys	Lys	Cys	Ser	Thr	Ser	Pro	Leu	Leu	Glu	
	690						695					700					
25	Ala	Cys	Glu	Phe	Leu	Arg	Lys										
	705					710											
	<210> 7																
	<211> 35																
	<212> PRT																
	<213> Artificial Sequence																
	<220>																
	<223> synthetic peptide																
30	<400> 7																
35	Glu	Pro	Tyr	Phe	Gly	Tyr	Ser	Gly	Ala	Phe	Lys	Cys	Leu	Gln	Asp	Gly	
	1				5					10					15		
40	Ala	Gly	Asp	Val	Ala	Phe	Val	Lys	Glu	Thr	Thr	Val	Phe	Glu	Asn	Leu	
				20					25					30			
45	Pro	Glu	Lys														
			35														
	<210> 8																
	<211> 11																
	<212> PRT																
	<213> Artificial Sequence																
	<220>																
50	<223> synthetic peptide																
	<400> 8																
55	Ser	Val	Asp	Gly	Lys	Glu	Asp	Leu	Ile	Trp	Lys						
	1				5						10						
	<210> 9																
	<211> 10																

EP 2 734 543 B1

<212> PRT
 <213> Artificial Sequence

 <220>
 5 <223> synthetic peptide

 <400> 9

 10 Val Asp Ser Ala Leu Tyr Leu Gly Ser Arg
 1 5 10

 <210> 10
 <211> 12
 <212> PRT
 15 <213> Artificial Sequence

 <220>
 <223> synthetic peptide

 20 <400> 10

 Phe Phe Ser Ala Ser Cys Val Pro Cys Ile Asp Arg
 1 5 10

 25 <210> 11
 <211> 26
 <212> PRT
 <213> Artificial Sequence

 30 <220>
 <223> synthetic peptide

 <400> 11

 35 Trp Phe Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala
 1 5 10 15

 Pro Ser Ile Thr Cys Val Arg Arg Ala Phe
 40 20 25

 <210> 12
 <211> 11
 <212> PRT
 45 <213> Artificial Sequence

 <220>
 <223> synthetic peptide

 50 <400> 12

 Trp Cys Thr Ile Ser Gln Pro Glu Trp Phe Lys
 1 5 10

 55 <210> 13
 <211> 11
 <212> PRT
 <213> Artificial Sequence

EP 2 734 543 B1

<220>

<223> synthetic peptide

<400> 13

5

Lys Leu Gly Ala Pro Ser Ile Thr Cys Val Arg
1 5 10

<210> 14

10

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

15

<223> synthetic peptide

<400> 14

20

Arg Ala Phe Ala Leu Glu Cys Ile Arg
1 5

<210> 15

<211> 21

<212> PRT

25

<213> Artificial Sequence

<220>

<223> synthetic peptide

30

<400> 15

Lys Ala Asp Ala Val Thr Leu Asp Gly Gly Met Val Phe Glu Ala Gly
1 5 10 15

35

Arg Asp Pro Tyr Lys
20

<210> 16

40

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

45

<223> synthetic peptide

<400> 16

50

Leu Arg Pro Val Ala Ala Glu Ile Tyr Gly Thr Lys
1 5 10

<210> 17

<211> 14

<212> PRT

55

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 17

Glu Ser Pro Gln Thr His Tyr Tyr Ala Val Ala Val Val Lys
 1 5 10

<210> 18

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 18

Lys Gly Ser Asn Phe Gln Leu Asp Gln Leu Gln Gly Arg
 1 5 10

<210> 19

<211> 65

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 19

Leu Gln Gly Ala Val Ala Lys Phe Phe Ser Ala Ser Cys Val Pro Cys
 1 5 10 15

Ile Asp Arg Gln Ala Tyr Pro Asn Leu Cys Gln Leu Cys Lys Gly Glu
 20 25 30

Gly Glu Asn Gln Cys Ala Cys Ser Ser Arg Glu Pro Tyr Phe Gly Tyr
 35 40 45

Ser Gly Ala Phe Lys Cys Leu Gln Asp Gly Ala Gly Asp Val Ala Phe
 50 55 60

Val
 65

Claims

1. A method for assessing resolution of inflammation in a subject, comprising determining the presence of a lactoferrin fragment characteristic of resolution having a molecular weight of about 17 kDa in a sample obtained from an inflammatory tissue or from body fluids of the subject, and quantifying the amount of the lactoferrin fragment in the sample, wherein the presence of said fragment in said sample, in an amount significantly higher than its amount in a control sample corresponding to a subject having non-resolving inflammation and/or a healthy subject, indicates that said subject has inflammation in resolution, wherein said fragment comprises an amino acid sequence corresponding to positions 172-342 of mammalian lactoferrin, or wherein the fragment characteristic of resolution having a molecular weight of about 17 kDa comprises at least one

of SEQ ID NOs: 7-10.

2. The method of claim 1,
wherein said fragment comprises an amino acid sequence corresponding to positions 172-342 of human or bovine lactoferrin; or
wherein the fragment characteristic of resolution having a molecular weight of about 17 kDa comprises SEQ ID NOs: 7-10.
3. The method of claim 1,
further comprising quantifying the amounts of lactoferrin fragments in said sample, and determining the ratio of the amount of the lactoferrin fragment characteristic of resolution to the amount of a lactoferrin fragment having a molecular weight of about 15 kDa, wherein said fragments comprise an amino acid sequence corresponding to positions 172-342 and 20-182 of mammalian lactoferrin, respectively, and wherein a ratio significantly higher than that determined for a control sample corresponding to a subject having non-resolving inflammation indicates that said subject has inflammation in resolution, preferably wherein a ratio of at least 3 indicates that said subject has inflammation in resolution.
4. The method of claim 1, wherein the sample is obtained from body fluids selected from the group consisting of milk, blood, urine and lymph samples, and samples obtained from uterine fluid, vaginal secretion, saliva, bile, pancreatic juice, small intestine secretions, nasal secretion, colostrums and tears, preferably wherein the sample is a milk sample.
5. The method of claim 1 for monitoring the progression of inflammatory resolution in a subject in need thereof, further comprising determining the amount of the lactoferrin fragment characteristic of resolution having a molecular weight of about 17 kDa in a first sample obtained from the subject at a first time point, and in a second sample obtained from said subject at a second subsequent time point,
wherein an increase in the amount of said fragment in the second sample compared to the first sample indicates a positive progression of inflammatory resolution.
6. The method of claim 1, wherein said fragment comprises an amino acid sequence corresponding to positions 172-342 of human or bovine lactoferrin, preferably wherein said fragment has an amino acid sequence as set forth in SEQ ID NO: 1 or in SEQ ID NO: 2.
7. The method according to claim 1, wherein the subject is selected from humans and non-human mammals, preferably wherein the subject is human or bovine or a lactating mammal.
8. The method according to claim 1, wherein the inflammation is associated with an infection.
9. The method of claim 8
wherein the infection is a bacterial infection, a viral infection, a fungal infection or a parasitic infection, preferably associated with *E. coli* infection, more preferably with mastitis; or
wherein the inflammation is associated with peritonitis.
10. A method for determining whether a subject having an inflammatory disease is a candidate for a treatment for the disease, comprising assessing the resolution of inflammation in the subject by determining the presence of a lactoferrin fragment characteristic of resolution having a molecular weight of about 17 kDa in a sample obtained from said subject, wherein the presence of the fragment in said sample indicates that said subject has inflammation in resolution and the absence of resolution indicates that said subject is a candidate for the treatment,
wherein said fragment comprises an amino acid sequence corresponding to positions 172-342 of mammalian lactoferrin, or
wherein the fragment characteristic of resolution has a molecular weight of about 17 kDa comprises at least one of SEQ ID NOs: 7-10.
11. The method of claim 10,
wherein said fragment comprises an amino acid sequence corresponding to positions 172-342 of human or bovine lactoferrin; or
wherein said fragment has an amino acid sequence as set forth in any one of SEQ ID NOs: 1 and 2.

12. A kit for assessing the presence or absence of resolving inflammation in a subject, comprising means for determining the presence of a lactoferrin fragment characteristic of resolution having a molecular weight of about 17 kDa in a sample;
 wherein the means comprise an antibody specifically recognizing an isolated lactoferrin fragment characteristic of resolution and having a molecular weight of about 17kDa, the fragment having an amino acid sequence as set forth in any one of SEQ ID NOs: 1 and 2, wherein binding of the antibody to said fragment is not competitively inhibited by the presence of an isolated lactoferrin fragment having an amino acid sequence as set forth in any one of SEQ ID NOs: 3 and 4,
 the kit further comprising one or more isolated lactoferrin fragments selected from the group consisting of:
- a.) An isolated lactoferrin fragment characteristic of resolution having a molecular weight of about 17kDa, the fragment having an amino acid sequence as set forth in any one of SEQ ID NOs: 1 and 2 or at least 90% amino acid identity thereto; and
 - b.) An isolated lactoferrin fragment having a molecular weight of about 15kDa, the fragment having an amino acid sequence as set forth in any one of SEQ ID NOs: 3 and 4 or at least 90% amino acid identity thereto.
13. The kit of claim 12, wherein said one or more lactoferrin fragments is selected from the group consisting of SEQ ID NOs: 1, 2, 3 and 4.

Patentansprüche

1. Verfahren zur Bestimmung des Abklingens einer Entzündung in einem Individuum, welches umfasst, Bestimmen der Anwesenheit eines Lactoferrin-Fragments, das kennzeichnend ist für das Abklingen und ein Molekulargewicht von etwa 17 kDa aufweist, in einer Probe, die von einem entzündlichen Gewebe oder von Körperflüssigkeiten des Individuums erhalten wurde, und Quantifizieren der Menge des Lactoferrin-Fragments in der Probe, wobei die Anwesenheit des Fragments in der Probe in einer Menge erheblich höher als dessen Menge in einer Kontroll-Probe entsprechend einem Individuum ohne abklingende Entzündung und/oder einem gesunden Individuum anzeigt, dass das Individuum eine abklingende Entzündung aufweist, wobei das Fragment eine Aminosäuresequenz entsprechend den Positionen 172-342 des Säuger-Lactoferrin umfasst, oder wobei das Fragment, das kennzeichnend ist für ein Abklingen und ein Molekulargewicht von etwa 17 kDa aufweist, mindestens eine der SEQ ID NOs: 7-10 umfasst.
2. Verfahren nach Anspruch 1, wobei das Fragment eine Aminosäuresequenz umfasst, entsprechend den Positionen 172-342 des humanen oder Rinder-Lactoferrin; oder wobei das Fragment, das kennzeichnend ist für ein Abklingen und ein Molekulargewicht von etwa 17 kDa aufweist, SEQ ID NOs: 7-10 umfasst
3. Verfahren nach Anspruch 1, welches weiter umfasst, Quantifizieren der Mengen an Lactoferrin-Fragmenten in der Probe, und Bestimmen des Verhältnisses der Menge des Lactoferrin-Fragments, das kennzeichnend ist für ein Abklingen mit der Menge eines Lactoferrin-Fragments mit einem Molekulargewicht von etwa 15 kDa, wobei das Fragments eine Aminosäuresequenz entsprechend des Positionen 172-342 bzw. 20-182 des Säuger-Lactoferrin umfasst, und wobei ein Verhältnis erheblich höher als die für eine Kontroll-Probe bestimmte, die einem Individuum ohne abklingende Entzündung entspricht, anzeigt, dass das Individuum eine abklingende Entzündung aufweist, vorzugsweise wobei ein Verhältnis von mindestens 3 anzeigt, dass das Individuum eine abklingende Entzündung aufweist.
4. Verfahren nach Anspruch 1, wobei die Probe aus Körperflüssigkeiten erhalten wird, ausgewählt aus der Gruppe bestehend aus Milch-, Blut-, Urin- und Lymph-Proben, und Proben, erhalten aus Uterus-Flüssigkeit, Vaginal-Sekret, Speichel, Gallenflüssigkeit, Pankreassaft, Sekreten des Dünndarms, Nasensekreten, Erstmilch und Tränen, vorzugsweise wobei die Probe eine Milchprobe ist.
5. Verfahren nach Anspruch 1 zur Überwachung des Fortschreitens des Abklingens einer Entzündung in einem dieses benötigenden Individuums, welches weiter umfasst, Bestimmen der Menge des Lactoferrin-Fragments, das kennzeichnend ist für ein Abklingen und ein Molekulargewicht von etwa 17 kDa aufweist, in einer ersten Probe, die von dem Individuum zu einem ersten Zeitpunkt erhalten wurde, und in einer zweiten Probe, die von dem Individuum zu

einem zweiten, nachfolgenden Zeitpunkt erhalten wurde,
wobei ein Anstieg der Menge des Fragments in der zweiten Probe im Vergleich zu der ersten Probe einen positiven Fortschritt des Abklingens der Entzündung anzeigt.

- 5 **6.** Verfahren nach Anspruch 1, wobei das Fragment eine Aminosäuresequenz entsprechend den Positionen 172-342 des humanen oder Rinder-Lactoferrin umfasst, vorzugsweise wobei das Fragment eine Aminosäuresequenz gemäß SEQ ID NO: 1 oder SEQ ID NO: 2 aufweist.
- 10 **7.** Verfahren nach Anspruch 1, wobei das Individuum ausgewählt ist unter menschlichen oder nicht-menschlichen Säugern, vorzugsweise wobei das Individuum ein Mensch oder ein Rind oder ein laktierender Säuger ist.
- 8.** Verfahren nach Anspruch 1, wobei die Entzündung mit einer Infektion assoziiert ist.
- 15 **9.** Verfahren nach Anspruch 8
wobei die Infektion eine bakterielle Infektion ist, eine virale Infektion, eine Pilz-Infektion oder eine Parasiten-Infektion, vorzugsweise mit einer *E. coli* Infektion assoziiert, mehr bevorzugt mit Mastitis; oder
wobei die Entzündung mit Peritonitis assoziiert ist.
- 20 **10.** Verfahren zur Bestimmung, ob ein Individuum, die an einer entzündliche Erkrankung leidet, ein Kandidat für eine Behandlung der Erkrankung ist, welches umfasst, Bestimmen des Abklingens der Entzündung in dem Individuum durch Bestimmen der Anwesenheit eines Lactoferrin-Fragments, das kennzeichnend ist für ein Abklingen und ein Molekulargewicht von etwa 17 kDa aufweist, in einer Probe, die von dem Individuum erhalten wurde, wobei die Anwesenheit des Fragments in der Probe anzeigt, dass das Individuum ein abklingende Entzündung aufweist und die Abwesenheit eines Abklingens anzeigt, dass das Individuum ein Kandidat für die Behandlung ist,
25 wobei das Fragment eine Aminosäuresequenz umfasst, entsprechend den Positionen 172-342 des Säuger-Lactoferrins, oder
wobei das Fragment, das kennzeichnend ist für ein Abklingen und ein Molekulargewicht von etwa 17 kDa aufweist, mindestens eine der SEQ ID NOs: 7-10 umfasst.
- 30 **11.** Verfahren nach Anspruch 10,
wobei das Fragment eine Aminosäuresequenz entsprechend den Positionen 172-342 des humanen oder Rinder-Lactoferrin umfasst; oder
wobei das Fragment eine Aminosäuresequenz gemäß einer der SEQ ID NOs: 1 und 2 aufweist.
- 35 **12.** Kit zur Bestimmung der Anwesenheit oder Abwesenheit des Abklingens einer Entzündung in einem Individuum, welcher Mittel umfasst zur Bestimmung der Anwesenheit eines Lactoferrin-Fragments, das kennzeichnend ist für ein Abklingen und ein Molekulargewicht von etwa 17 kDa aufweist, in einer Probe;
wobei das Mittel einen Antikörper umfasst, der spezifisch ein isoliertes Lactoferrin-Fragment erkennt, das kennzeichnend ist für ein Abklingen und ein Molekulargewicht von etwa 17 kDa aufweist, worin das Fragment eine Aminosäuresequenz gemäß einer der SEQ ID NOs: 1 und 2 aufweist, wobei eine Bindung des Antikörpers an das
40 Fragment nicht kompetitiv durch die Anwesenheit eines isolierten Lactoferrin-Fragments mit einer Aminosäuresequenz gemäß einer der SEQ ID NOs: 3 und 4 verhindert wird,
worin der Kit weiter ein oder mehrere isolierte Lactoferrin-Fragmente umfasst, ausgewählt aus der Gruppe bestehend aus:
45 a.) einem isolierten Lactoferrin-Fragment, das kennzeichnend ist für ein Abklingen und ein Molekulargewicht von etwa 17 kDa aufweist, worin das Fragment eine Aminosäuresequenz gemäß einer der SEQ ID NOs: 1 und 2 aufweist oder mindestens 90% Aminosäure-Identität dazu; und
b.) einem isolierten Lactoferrin-Fragment mit einem Molekulargewicht von etwa 15 kDa, worin das Fragment eine Aminosäuresequenz gemäß einem der SEQ ID NOs: 3 und 4 aufweist oder mindestens 90% Aminosäure-Identität dazu.
50 **13.** Kit nach Anspruch 12, worin das eine oder die mehreren Lactoferrin-Fragmente ausgewählt sind aus der Gruppe bestehend aus SEQ ID NOs: 1, 2, 3 und 4.
- 55

Revendications

1. Procédé pour évaluer la résolution d'une inflammation chez un sujet, comprenant la détermination de la présence d'un fragment de lactoferrine caractéristique de la résolution ayant un poids moléculaire d'environ 17 kDa dans un échantillon obtenu à partir d'un tissu inflammatoire ou de fluides corporels du sujet, et la quantification de la quantité du fragment de lactoferrine dans l'échantillon, dans lequel la présence dudit fragment dans ledit échantillon, dans une quantité significativement supérieure à sa quantité dans un échantillon témoin correspondant à un sujet présentant une inflammation non résolue et/ou un sujet sain, indique que ledit sujet présente une inflammation au cours de la résolution,
dans lequel ledit fragment comprend une séquence d'acides aminés correspondant aux positions 172-342 de la lactoferrine de mammifère, ou
dans lequel le fragment caractéristique de la résolution ayant un poids moléculaire d'environ 17 kDa comprend au moins une des séquences SEQ ID NO : 7-10.
2. Procédé selon la revendication 1,
dans lequel ledit fragment comprend une séquence d'acides aminés correspondant aux positions 172-342 de la lactoferrine humaine ou bovine ; ou
dans lequel le fragment caractéristique de la résolution ayant un poids moléculaire d'environ 17 kDa comprend la séquence SEQ ID NO : 7-10.
3. Procédé selon la revendication 1,
comprenant en outre la quantification des quantités de fragments de lactoferrine dans ledit échantillon, et la détermination du rapport de la quantité du fragment de lactoferrine caractéristique de la résolution sur la quantité d'un fragment de lactoferrine ayant un poids moléculaire d'environ 15 kDa, dans lequel lesdits fragments comprennent respectivement une séquence d'acides aminés correspondant aux positions 172-342 et 20-182 de la lactoferrine de mammifère, et dans lequel un rapport significativement supérieur à celui déterminé pour un échantillon témoin correspondant à un sujet présentant une inflammation non résolue indique que ledit sujet présente une inflammation au cours de la résolution, de préférence dans lequel un rapport d'au moins 3 indique que ledit sujet présente une inflammation au cours de la résolution.
4. Procédé selon la revendication 1, dans lequel l'échantillon est obtenu à partir de fluides corporels choisis dans le groupe constitué d'échantillons de lait, de sang, d'urine et de lymphe et d'échantillons obtenus à partir de liquide utérin, de sécrétion vaginale, de salive, de bile, de suc pancréatique, de sécrétions de l'intestin grêle, de sécrétions nasales, de colostrums et de larmes, de préférence dans lequel l'échantillon est un échantillon de lait.
5. Procédé selon la revendication 1 pour surveiller la progression de la résolution inflammatoire chez un sujet en ayant besoin, comprenant en outre la détermination de la quantité du fragment de lactoferrine caractéristique d'une résolution ayant un poids moléculaire d'environ 17 kDa dans un premier échantillon obtenu à partir du sujet à un premier instant, et dans un second échantillon obtenu à partir dudit sujet à un second instant ultérieur,
dans lequel une augmentation de la quantité dudit fragment dans le deuxième échantillon comparé au premier échantillon indique une progression positive de la résolution inflammatoire.
6. Procédé selon la revendication 1, dans lequel ledit fragment comprend une séquence d'acides aminés correspondant aux positions 172-342 de lactoferrine humaine ou bovine, de préférence dans lequel ledit fragment possède une séquence d'acides aminés telle que définie dans la séquence SEQ ID NO : 1 ou dans la séquence SEQ ID NO : 2.
7. Procédé selon la revendication 1, dans lequel le sujet est choisi parmi des humains et des mammifères non humains, de préférence dans lequel le sujet est un humain ou un bovin ou un mammifère en période de lactation.
8. Procédé selon la revendication 1, dans lequel l'inflammation est associée à une infection.
9. Procédé selon la revendication 8,
dans lequel l'infection est une infection bactérienne, une infection virale, une infection fongique ou une infection parasitaire, de préférence associée à une infection par E. coli, plus particulièrement avec une mammites ; ou
dans lequel l'inflammation est associée à une péritonite.
10. Procédé pour déterminer si un sujet souffrant d'une maladie inflammatoire est un candidat pour un traitement de la maladie, comprenant l'évaluation de la résolution de l'inflammation chez le sujet en déterminant la présence du

fragment de lactoferrine caractéristique de la résolution ayant un poids moléculaire d'environ 17 kDa dans un échantillon obtenu à partir dudit sujet, dans lequel la présence du fragment dans ledit échantillon indique que ledit sujet possède une inflammation au cours de la résolution et l'absence de résolution indique que ledit sujet est candidat pour le traitement,

dans lequel ledit fragment comprend une séquence d'acides aminés correspondant aux positions 172-342 de lactoferrine de mammifère, ou

dans lequel le fragment caractéristique de la résolution possède un poids moléculaire d'environ 17 kDa qui comprend au moins une des séquences SEQ ID NO : 7-10.

11. Procédé selon la revendication 10,

dans lequel ledit fragment comprend une séquence d'acides aminés correspondant aux positions 172-342 de lactoferrine humaine ou bovine, ou

dans lequel ledit fragment possède une séquence d'acides aminés telle que définie dans l'une des séquences SEQ ID NO : 1 et 2.

12. Kit pour évaluer la présence ou l'absence de la résolution d'une inflammation chez un sujet, comprenant des moyens pour déterminer la présence du fragment de lactoferrine caractéristique de la résolution ayant un poids moléculaire d'environ 17 kDa dans un échantillon :

dans lequel les moyens comprennent un anticorps reconnaissant spécifiquement un fragment isolé de lactoferrine caractéristique de la résolution et ayant un poids moléculaire d'environ 17 kDa, le fragment ayant une séquence d'acides aminés telle que définie dans l'une quelconque des séquences SEQ ID NO : 1 et 2, dans lequel la liaison de l'anticorps audit fragment n'est pas inhibée de manière compétitive par la présence d'un fragment isolé de lactoferrine ayant une séquence d'acides aminés telle qu'indiquée dans l'une quelconque des séquences SEQ ID NO : 3 et 4,

le kit comprenant en outre un ou plusieurs fragments isolés de lactoferrine choisi à partir du groupe constitué par :

a) un fragment isolé de lactoferrine caractéristique de la résolution ayant un poids moléculaire d'environ 17 kDa, le fragment ayant une séquence d'acides aminés telle que définie dans l'une quelconque des séquences SEQ ID NO : 1 et 2 ou au moins 90% d'identité en acides aminés avec ceux-ci ; et

b) un fragment isolé de lactoferrine ayant un poids moléculaire d'environ 15 kDa, le fragment ayant une séquence d'acides aminés telle que définie dans l'une quelconque des séquences SEQ ID NO : 3 et 4 ou au moins 90% d'identité en acides aminés avec ceux-ci.

13. Kit selon la revendication 12, dans lequel ledit un ou plusieurs fragments de lactoferrine est choisi à partir du groupe constitué par les séquences SEQ ID NO : 1, 2, 3 et 4.




Figure 1




Figure 2A




Figure 2B




Figure 3A




Figure 3B




Figure 3C




Figure 3D




Figure 4A




Figure 4B

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- JP 2004155751 B [0012]
- US 20070197426 A [0013]
- JP 2003289749 A [0013]
- WO 0239883 A [0017]
- US 4376110 A [0085]
- US 4036945 A [0087]
- US 4331647 A [0087]
- US 4946778 A [0089]

Non-patent literature cited in the description

- **BANNENBERG et al.** *J Immunol.*, 2005, vol. 1;174 (7), 4345-55 [0006]
- **SCHIF-ZUCK et al.** *Eur J Immunol.*, 2011, vol. 41 (2), 366-79 [0007]
- **KANYSHKOVA et al.** *Biochemistry*, 2001, vol. 66 (1), 1-7 [0009]
- **VOGEL et al.** *Biochem Cell Biol.*, 2002, vol. 80 (1), 49-63 [0011]
- **KOMINE et al.** *Mol Immunol.*, March 2007, vol. 44 (7), 1498-508 [0014]
- **KOMINE et al.** *J Vet Med Sci.*, July 2006, vol. 68 (7), 715-23 [0015]
- **KOMINE et al.** *J Vet Med Sci.*, March 2006, vol. 68 (3), 205-11 [0016]
- *J Vet Med Sci.*, July 2005, vol. 67 (7), 667-77 [0016]
- **JESAITIS et al.** *J Immunol*, 2003, vol. 171 (8), 4329-4339 [0018]
- Current Protocols in Immunology. John Wiley & Sons, Inc, 1992 [0083]
- **AUSUBEL et al.** Current Protocols in Molecular Biology. John Wiley & Sons, 1994, vol. I-III [0085]
- **HARLOW, E. ; LANE, D.** Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, 1988 [0086]
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Springs Harbor Laboratory, 1989 [0120]

专利名称(译)	乳铁蛋白片段及其用途		
公开(公告)号	EP2734543B1	公开(公告)日	2018-10-03
申请号	EP2012818296	申请日	2012-07-24
[标]申请(专利权)人(译)	海法卡梅尔大学经济有限公司		
申请(专利权)人(译)	卡梅尔海法大学经济CORP.		
当前申请(专利权)人(译)	卡梅尔海法大学经济CORP.		
[标]发明人	ARIEL AMIRAM LUTATY AVIV		
发明人	ARIEL, AMIRAM LUTATY, AVIV		
IPC分类号	C07K14/79 C07K16/18 G01N33/53 G01N33/48		
CPC分类号	G01N33/53 C07K14/79 G01N27/447 G01N33/68 G01N2333/79 G01N2800/52 G01N2800/56 G01N2800/7095		
优先权	61/511056 2011-07-24 US		
其他公开文献	EP2734543A1 EP2734543A4		
外部链接	Espacenet		

摘要(译)	MKLFVPALLS	LGALGLCLAA	PRKNVRWCTI	SQPEWFKCRR	WQWRMKKLG
新的乳铁蛋白片段，其在解析期间是炎症的特征并且其用途。用于评估分辨炎症的存在或不存在以及用于监测受试者中炎症消退的进展的诊断组合物和方法。用于治疗患有炎性疾病的受试者的方法，所述方法包括通过测定乳铁蛋白片段的分子量来确定受试者是否具有分辨性炎症。	PSITCVRRAF	ALECIRIAIE	KKADAVTLDG	GMVFEAGRDP	YKLRPVAAEI
	YGTKEPQTH	YYAVAVVKKG	SNFQLDQLQG	RKSCHTGLGR	SAGWVIPMGI
	LRPYLSWTES	LEPLQGAVAK	FFSASCVPCI	DRQAYPNLCQ	LCKGEGENQC
	ACSSREPYFG	YSGAFKCLQD	GAGDVAFVKE	TTVFENLPEK	ADRDQYELLC
	LNNSRAPVDA	FKECHLAQVP	SHAVVARSVD	GKEDLIWKLL	SKAQEKFGKN
	KSRSFQLFGS	PPGQRDLLFK	DSALGFLRIP	SKVDSALYLG	SRYLTTLKNL
	RETAEVVKAR	YTRVVWCAVG	PEEQKKCQOW	SQQSGQNVTC	ATASTDDCI
	VLVLKGEADA	LNLDGGYIYT	AGKCGLVPVL	AENRKTSKYS	SLDCVLRPTE
	GYLAVAVVKK	ANEGLTWNSL	KDKKSCHTAV	DRTAGWNIPM	GLIVNQTGSC
	AFDEFFSQSC	APGRDPKSRL	CALCAGDDQG	LDKCVNSKE	KYYGYTGAFR
	CLAEDVGDA	FVKNDTVWEN	TNGESTADWA	KNLNREDFRL	LCLDGRKPV
	TEAQSCHLAV	APNHAVVSRS	DRAAHVKQVL	LHQQALFGKN	GKNCPDKFCL
	FKSETKNLLF	NDNTECLAKL	GGRPTYEEYL	GTEYVTAIAN	LKKCSTSPLL
					EACAFLTR